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Candida glabrata is an opportunist human fungal pathogen which causes 
disease in immuno-compromised patients and is highly drug resistant to 
commonly prescribed anti-fungal drugs such as Fluconazole. This project tested 
whether Lonidamine (LND) has potential as a new antifungal agent. LND has 
shown to be safe in the mouse model so suggests it can be used in humans and 
has also recently been shown to inhibit Succinate dehydrogenase (complex II of 
the mitochondrial respiratory chain). LND caused a reduction in the C. glabrata 
biofilm and its ability to form colonies. Flocculation during growth assays 
suggested that LND causes disruptions of the cell wall. Respirometry analysis 
suggested LND does not utilise the ETC when SDH is inhibited and relies on the 
compensatory metabolic pathway known as the glyoxylate cycle. Through S. 
cerevisiae mutant studies, weak points within metabolic pathways were found to 
be ICL1 (within the glyoxylate cycle) and LSC2 (within the TCA cycle). Future 
research on combinational drug therapy of using LND alongside inhibitors of 










1. Introduction    
1.1 C. glabrata and S. cerevisiae cellular structure 
 
Many yeasts, such as S. cerevisiae, are harmless and used in a variety of food 
and bioprocessing processes. Others, such as C. glabrata, are pathogens that 
represent a real clinical threat. Yeasts are eukaryotes and such they share 
conserved biochemical processes and intracellular compartments with human 
cells. This represents a problem when it comes to designing drugs to target 
fungal pathogens. The conservation means that components such as signalling 
receptors, enzymes, transporters, motor proteins, protein or DNA synthesis 
regulators that might normally act as good targets for drug development in 
prokaryotes are more problematic as they may prove toxic. All yeasts contain a 
thick cell wall which acts as a defensive mechanism to external factors, and this 
structure is not found in mammalian cells. The cell wall is therefore one of the 
primary targets for anti-fungal drugs that are currently used in the clinic. The cell 
wall is composed of an outer facing oligosaccharide layer which connects to 
mannoproteins and has an underlying matrix of glucan and chitin. The 
echinocandin class of antifungals targets the enzyme 1,3-β glucan synthase and 
so impairs cell wall synthesis. The cell wall is anchored to the plasma 
membrane via glucan connections and contains integral proteins responsible for 
cell wall synthesis. 




Ergosterol is a sterol which is found within fungi but not mammalian cells. It 
regulates both the membrane fluidity and structure. This highlights another 
target which is good for anti-fungal drugs and the azole class of drugs utilise 
this. The available antifungal classes interfering with ergosterol synthesis affect 
the products of the ERG11 gene (14α-demethylase; azoles), the ERG1 gene 
(squalene epoxidase; allylamines), and the ERG2 gene (sterol C-8 isomerase; 
morpholines). The potential of the 22 remaining genes required for ergosterol 
biosynthesis as antifungal targets remains to be explored (Rodrigues, 2018). 
Fluconazole which is the most commonly prescribed antifungal drug has 
mechanisms of actions that inhibit the cytochrome P450 enzyme lanosterol 
demethylase (14α-demethylase), encoded by ERG11, in the ergosterol 
biosynthesis pathway. This prevents ergosterol biosynthesis and consequently 
produces toxins as methylated sterols accumulate within the fungal cellular 
membrane.  
 
In the US, C. glabrata have higher rates of fluconazole resistance (11–13%) 
than C. albicans (0.5–2%), C. tropicalis (4–9%) and C. parapsilosis (2–6%) 
(Cleveland et al., 2012). In the UK, the inherent drug resistance of C. glabrata 
has risen, while C. albicans resistance has not risen above 1% for fluconazole in 
England in 2018 (Public Health England, 2017). C. glabrata susceptibility test 
results to C. glabrata isolates over the years of 2015-2017 show that 
voriconazole and fluconazole resistance has fluctuated, between 13% - 17% for 
voriconazole, and 12% - 20% for fluconazole (Public Health England, 2017). 
This further provides evidence for need of new development of new drug target. 





1.2 Candida species as human fungal pathogens 
 
Candida are among the most common human pathogenic fungi; the majority of 
the human population carries members of the genus Candida on their mucous 
membranes. The overwhelming majority (>90%) of Candida infections are 
caused by only four species: C. albicans (>50% of all cases), C. glabrata, C. 
parapsilosis, and C. tropicalis. C. albicans, C. parapsilosis and C. tropicalis 
belong to the CTG clade, a phylogenetic group that translates the CTG codon 
into serine instead of leucine (Butler et al., 2009).  
 
 
Figure 1. Phylogeny of sequenced Candida and Saccharomyces clade species. 
The asterisk marks a branch that was constrained on the basis of syntenic 
conservation (Butler et al., 2009) 
  
Mucosal infections, known as Candidiasis but more commonly as thrush, are 
easily treated in most cases but can be associated with significant morbidity.    
Candida bloodstream infections, also known as Candidemia, are difficult to treat 




and Arendrup, 2015). Although C. albicans represents the most prevalent 
human fungal pathogen, the variations in mortality and geographical spread are 
reported. For example it has been noted mortality can be higher in patients with 
Candida species that aren’t C. albicans compared to C. albicans itself 
(Montagna et al., 2014) and C. glabrata is commonly isolated in the German-
speaking countries, France, UK and North Europe; C.parapsilosis is more highly 
represented in Turkey, Greece and Spain (Montagna et al., 2014).  
      
Invasive candidiasis (IC) is a leading cause of mycosis-associated mortality in 
the United States. Candidiasis was the cause for approximately 0.4 deaths per 
100,000 population, since 1997 (Pfaller and Diekema, 2007). C.glabrata has 
emerged as the second most common cause of IC in the United States (Pfaller 
and Diekema, 2007). This data highlights the crucial importance of keeping a 
wider scope of research for fungal pathogens. 
 
1.3 Biofilms as a virulence factor associated with 
Candida glabrata 
 
C. glabrata is able to form a biofilm and this has been linked to its pathogenicity 
(Fidel, Vazquez and Sobel, 1999) and drug resistance as it has been shown that 
cells in the biofilm environment are up to 1000-fold more azole resistant than 
their planktonic counterparts, making azoles an ineffective biofilm treatment 
option (Ramage et al., 2012). These extracellular matrix-embedded structures 
appear on both biotic and abiotic surfaces. C. glabrata utilise biofilms as a 




structure of yeast cells nested within the extracellular matrix. C. glabrata has a 
unique biofilm which is high in both protein and carbohydrates whilst the C. 
parapsilosis biofilm matrices have large amounts of carbohydrate with less 
protein. Conversely, matrices extracted from C. tropicalis biofilms had low 
amounts of carbohydrate and protein (Silva et al., 2009). The high abundance of 
carbohydrates and proteins can act as a rich nutrient source within the biofilm 
that can allow for more than one species to co-exist within the biofilm in a 
synergistic manner. 
 
The ability to adhere to host tissue and initiate a biofilm relies on adhesins, such 
as the cell wall associated glycosylphosphatidylinositol (GPI) proteins (de Groot 
et al., 2008) . GPI proteins have an N-terminal ligand-binding sight along with a 
simple serine and threonine-rich region. These have tandem repeats which end 
with a C-terminus GPI-anchor attachment (de Groot et al., 2008). The epithelial 
adhesin EPA1 gene is suggested to be the most important role in the adhesion 
of C. glabrata to epithelial cells (Sundstrom, 2002). Following adherence to the 
host, cell division and proliferation leads to the forming of a basal layer of 
anchoring microcolonies (Silva et al., 2012). 
 
1.4 Drug resistance in C. glabrata 
 
C. glabrata has a natural multidrug (MDR: azole + echinocandin) adaptive 
resistance (Healey and Perlin, 2018). Currently azole resistance for C. glabrata 
isolates is 8% (Castanheira et al., 2017) but the worrying statistic is that whilst 




study which looked at 313 C. glabrata isolates from Duke Hospital showed that 
resistance to echinocandins increased from 4.9% to 12.3% in just a space of 9 
years (Alexander et al., 2013). Despite having a range of mechanisms for drug 
resistance, C. glabrata has shown to utilise the upregulation of multidrug 
transporters such as the CDR1 and PDH1, with preference for the latter having 
been shown (Vermitsky et al., 2006). The resistance to echinocandins does not 
appear to be by the same mechanisms as overexpression of CDR1 showed no 
increase in resistance to micafungin or caspofungin (Niimi et al., 2006).  
 
In several fungal species, respiratory stress has been linked with increased 
resistance to azole drugs (Shingu-Vazquez and Traven, 2011). When 
mitochondrial function is impaired in S. cerevisiae, the transcription 
factor PDR3 functions to increase the expression of efflux pump encoding 
genes, such as the ABC drug transporter PDR5. In C. glabrata a similar 
phenomena has been observed via CgPDR1 upregulating CDR1 and CDR2 
(Brun et al., 2004).  
 
Increased drug resistance in C. glabrata correlates with increased virulence and 
fitness of the strains expressing mutated CgPDR1 via up regulation of the efflux 
pump activity (Ferrari et al., 2009). Clinical isolates of C. glabrata have also 
shown higher levels of drug resistance that correlates with mitochondrial 






An article in 2004 (Vermitsky and Edlind, 2004) showed that C. glabrata induced 
upregulation of multidrug transporter genes CDR1 and PDH1 produced from 
rare mutations that are selected by drug pressure. As C. glabrata has shown 
resistance to commonly used clinical drugs such as azoles, the need to 
investigate other potential structures of the fungi have never been more 
important.  
 
1.5 The mitochondria and associated 
metabolic pathways of C. glabrata 
 
1.5.1 The mitochondria of C. glabrata as a new 
antifungal target 
 
C. glabrata is a haploid budding yeast and has a mitochondrial genome which is 
relatively small and consists of only 8 ORFs (open reading frames) which code 
for the three subunits of Cytochrome C oxidase, the apocytochrome b, the three 
subunits of ATP synthase and the ribosomal protein VAR1. As well as 2 rNAs, 
23 tRNAs and 1 non-coding RNA (Koszul et al., 2003).  A notable difference 
structurally in terms of the electron transport chain (ETC) to that of other 
Candida species is that it does not contain a multi-subunit Complex I or an AOX 
enzyme (Sun et al., 2005). Respiration deficiency leads to attenuated virulence 
in the fungal pathogen (Brun et al., 2005). This may make the respiratory chain 
a potentially easier target for mitochondrial inhibition than other fungal 




inhibition of electron transport alone may not be sufficient. C. glabrata depend 
on oxidative phosphorylation for virulence. 
 
Disruption of the respiratory pathway at selected points can increase 
intracellular levels of reactive oxygen species in yeast (Barros, Netto and 
Kowaltowski, 2003). It has been shown that yeast strains which lack 
mitochondrial function are sensitized to oxidative stress due to reactive oxygen 
species (ROS). Literature suggests that oxidant sensitivity is due to a defect in 
an energy requiring process which is needed for ROS detoxification or repair 
due to oxidative damage (Grant, MacIver and Dawes, 1997). 
 
Recently, (Sun et al., 2019) an article was published which highlighted seven 
genes of the CTG clade which show promising therapeutic targets after it was 
shown that these play crucial roles in the ETC pathway. The ETC function in the 
mitochondria has a role on pathogenesis, growth, anti-fungal susceptibility and 
yeast-to-hyphae in the cases of C. albicans. With the mounting pressure from 
resistant strains, the mitochondria have become the new limelight target for 
antifungal drugs. 
      
Pharmacological approaches suggest that Antimycin A and Cyanide lead to 
inhibited growth and oxidative stress in C. albicans (Ruy, Vercesi and 
Kowaltowski, 2006). TTFA has shown to be a potent complex II inhibitor for the 
respiratory chain causing inhibition of mitochondrial respiration. Inhibition occurs 
by binding of TTFA to two ubiquinone binding sites, Qp and Qd. TTFA has been 




leads to oxidative stress. Collectively, these points suggest that targeting the 
mitochondria could provide a promising therapeutic approach. 
 
1.5.2 TCA and glyoxylate cycles 
 
 
Figure 2. A schematic of the tricarboxylic acid cycle 
 
Both S. cerevisiae and C. glabrata are able to live within aerobic and anaerobic 
conditions. With lacking oxygen, they can generate energy via glycolysis 
whereby glucose is broken down and converted to ethanol (less energetically 
favourable). With oxygen present, they can perform aerobic respiration whereby 
they glucose is broken down into CO2 and ATP is generated by both the TCA 
(tricarboxylic acid) cycle and the ETC (electron transport chain). The TCA cycle 




(product of glucose metabolism). Through a series of redox reactions, the 
energy is generated through NADH, FADH2 and ATP molecules along the cycle. 
It is the FADH2 and NADH which are donated to the ETC for the more 
energetically favourable oxidative phosphorylation. Surprisingly, being Crabtree 
positive means that they opt to perform fermentation to generate their ATP 
rather than the energetically favourable TCA and ETC mechanisms, even when 
in very rich glucose medium. 
 
Unlike mammalian cells, C. glabrata have a compensatory glyoxylate cycle 
which can provide intermediates back into the TCA cycle when it is 
dysfunctional. It also can be an adaptive mechanism for C. glabrata as it is an 
opportunist pathogen and can invade hosts which may not provide nutrient rich 
sources. The glyoxylate cycle allows for a certain degree of metabolic flexibility 
as it can utilise alternative carbon sources. Transcriptional analyses of 
macrophage engulfed C. glabrata have shown that key metabolic enzymes in 
the glyoxylate cycle were ICL1 and MLS1. (Chew, Chee and Than, 2019). This 
suggested that the microenvironment within the macrophage environment is 
deficient of glucose and initiated a metabolic switch within C. glabrata. It has 
been suggested already that engulfed C. glabrata cells utilise acetyl-CoA from 
the breakdown of fatty acids via the glyoxylate cycle as the main carbon source 








1.6 Fungal respiration as a potential anti-
fungal target 
 
1.6.1 Complex I inhibition 
 
Several Complex I (NADH:ubiquinone oxidoreductase) subunits have been 
shown to be fungal specific (Sharma, Lu and Bai, 2009). Eukaryotic complex I 
has a core of 14 alpha-proteobacterial subunit proteins and a variable number of 
supernumerary subunit proteins. Of the latter group of proteins, one (NUZM) is 
fungal-specific, and a second (NUXM) is found in fungi, algae and plants but is 
not a mammalian complex I subunit protein. These subunit proteins have been 
designated as Nuo1p and Nuo2p (NADH-ubiquinone oxidoreductases) (She et 
al., 2015). This highlights potential future drug targets which have yet to be fully 
investigated. Deletion of regulatory proteins of Complex I lead to both 
respiratory and virulence deficiencies in C. albicans (She et al., 2015). 
Rotenone, which inhibits complex I, has been shown to cause cell death that is 
linked to the accumulation of ROS (Li et al., 2011). Some yeasts, such as S. 
cerevisiae and C. glabrata do not possess a multi-subunit complex I and rely 
NADH dehydrogenase enzymes located on either the matrix or intermembrane 
space side of the inner mitochondrial membrane. The mitochondrial external 
NADH dehydrogenase are (NDE1 and NDE2) and a NADH Dehydrogenase 





Flavone, which is a specific inhibitor of the S. cerevisiae NDI1 has shown to 
inhibit almost completely NADH oxidase and NADH‐UQ1 reductase activities of 
NDI1 (Kitajima-Ihara and Yagi, 1998). 
 
1.6.2.1 Complex II (succinate dehydrogenase) 
 
 
Figure 3. The role of Complex II in the Mitochondrial  
respiratory chain (Sun et al., 2005) 
 
The mechanisms of complex II (succinate:ubiquinone oxidoreductase) begin 
with the catalysed oxidation of succinate to fumarate in the TCA which in turns 
donates electrons to ubiquinone in the inner mitochondrial membrane. The 
Succinate dehydrogenase (SDH) is crucial to aerobic respiration. SDH catalyses 
the oxidation of succinate into fumarate via the Krebs cycle. To note a differing 
factor is that it does not use soluble NAD+ intermediates. Succinate:ubiquinone 




the mitochondria and a membrane-integral domain that spans the membrane 
(Figure 3). The peripheral has a dicarboxylate binding site which consists of a 
flavoprotein and a covalently bound FAD. It is this FAD which is the substrate 
which removes two hydrogen electrons from the oxidation of succinate to 
fumarate. Three Iron-Sulfur clusters are present in the peripheral domain which 
are [2Fe-2S] cluster, a [4Fe-4S] cluster and a [3Fe-4S] cluster. The membrane-
integral domain acts to anchor the flavoprotein and Iron-Sulfur subunits to the 
membrane and is required for quinone reduction and oxidation (Hägerhäll, 
1997). It is suggested that electron transfer via the FAD substrate as FADH2 
then passes donated electrons through the iron sulphur clusters towards 







Figure 4. The Mitochondrial Respiratory Complex II Structure (Sun et al., 2005) 
  
The Succinate oxidation is coupled with Ubiquinone to Ubiquinol as part of the 
electron transport chain (within the inner membrane). The Ubiquinone acts as 
an electron carrier to complex III. This entire process links respiration to the 
TCA cycle, which provides intermediates for biosynthesis of macromolecules in 
addition to its role in supporting respiration. What makes complex II a 
particularly interesting target for this project is how it acts as a member of both 




a simpler means of NADH to form an electrochemical gradient across the inner 
mitochondrial membrane necessary for ATP production. 
      
The SDH enzyme is sensitive to thiol groups which originally have been shown 
to not play much importance in the binding or catalysis activity (Kregiel, 2012). 
As previously stated, Inhibitors of Complex II include TTFA which inhibits its 
quinone reduction activity by occupying its ubiquinone binding sites. It is shown 
(Figure 5C and 5D) that TTFA molecules are found in the proximity of [3Fe-4S] 





Figure 5. The Mitochondrial Respiratory Complex II Structure with binding 





3-nitropropionate (NPA), a succinate analogue which inhibits succinate-
oxidation enzymatic activity. NPA molecules are shown (Figure 5B) to be found 
near a Flavin mononucleotide group of FAD. Due to the electron density at the 
Succinate binding site, it suggests NPA interacts with the side chains A266 and 
His-A254 of the nitryl group. As well as the main chains of Glu-A267 and Gly-
A63 and the FMN group of FAD. The amide group of Gln-A252 anchors the 
carboxyl group one side while the guanidinium group of Arg-A409 and the 
imidazole group of His-A365 anchor the other side (Sun et al., 2005). 
      
The role of Complex II in the virulence of human fungal pathogens is not well 
understood and for this reason its inhibition needs further exploration as a 
possible antifungal therapy. It already has promising signs that the function of 
Complex II is linked to morphogenesis. A study showed inhibition of quinone 
reduction activity with TTFA was shown to completely inhibit filamentation in C. 
albicans (Watanabe et al., 2006). 
 
1.6.2.2 Lonidamine mechanisms of actions 
  
The mechanism of action that LND utilises is the same as seen by TTFA (Figure 
5C and 5D). When LND was administered succinate levels increased and 
Fumarate levels decreased. LND and NPA in combination induced a two-fold 
increase in succinate levels of the SDH enzyme (Guo et al., 2016). When TTFA 
was used in combination with LND, TTFA treatment resulted in a larger increase 




quinone reduction activity by occupying its ubiquinone binding sites. It is shown 
(Figure 5C and 5D) that TTFA molecules are found in the proximity of [3Fe-4S] 
and at the distal side of the transmembrane anchor, potentially the same as 
LND. As both drug molecules compete with each other’s binding sites, 
increasing doses of LND inhibition of SQR activity was found to be much greater 
than inhibition of SDH activity at all LND concentrations tested (Guo et al., 
2016). This could suggest that LND failed to fully block the electron transfer 
from the Iron-sulfur cluster to PMS (Phenazine Methosulfate) and MTT (artificial 
electron acceptors) that allow for a redirection past Ubiquinone. This provides 
further evidence that LND seems to inhibit complex II activity by the same 
mechanisms of TTFA which are the interference of the ubiquinone reduction 
site. 
 
An article in 1988 stated that Lonidamine had ~70% inhibition of mitochondrially 
bound hexokinase and aerobic glycolysis in Ehrlich ascites tumor cells 
(FLORIDI et al., 1988). In a more recent paper in 2015, the mechanisms of 
Lonidamine were highlighted in detail. The report states that a significant 
amount of succinate is accumulated in LND-treated cells. LND inhibits the 
formation of fumarate and malate and suppressed succinate-induced respiration 
of isolated mitochondria. LND also inhibits the succinate-ubiquinone reductase 
activity of respiratory complex II without fully blocking succinate dehydrogenase 
activity. LND also induced cellular reactive oxygen species through complex II. 
The ability of LND to promote cell death was potentiated by its suppression of 




glutathione generation. LND also increased glutaminolysis but decreased 
reductive carboxylation of glutamine-derived α-ketoglutarate (Guo et al., 2016). 
      
Very recently, LND which is a tumor-selective inhibitor of oxidative 
phosphorylation was modified into a Mito-LND form (Mitochondria targeting). 
The Mito-LND form showed to be 100-fold more potent than the original form. It 
inhibited mitochondrial bioenergetics in lung cell viability, growth progression 
and metastasis in mice (Cheng et al., 2019). Mito-LND caused no toxicity in 
mice even when administered for 8 weeks up to 50 times the effective inhibitory 
dose (Cheng et al., 2019). 
      
Malonate is known to be an inhibitor of the SDH enzyme and as it cannot be 
metabolised, this could act as a competitive inhibitor for complex II inhibition 
(Wojtovich,A.P et al. 2013). 
 
During the 1960’s complex II inhibitors were used in agriculture but due to their 
toxicity in mammalian cells, they cannot be utilised in the healthcare sector so 
LND could potentially be a solution. 
      
1.6.3 Complex III and complex IV 
 
Complex III and IV inhibitors are readily available, but most are too toxic for 
mammalian cells. An example of toxicity is Antimycin A which is a very potent 
complex III inhibitor. Human cells upon administration of Antimycin A have 




autophagy activity. It has been observed that antimycin A evoked dose-
dependent cell death, a rapid loss in mitochondrial membrane potential, and a 
collapse of oxidative phosphorylation (Hytti, M. et al. 2019). Complex III 
inhibition leads to G0/G1 arrest through redox alteration-mediated DNA damage 
response and regresses glioblastoma multiforme (in vivo mice model) as 
already shown by the novel mitochondrial complex-III inhibitor Mahanine 
(Bhattacharya, K. et al. 2014). 
 
Inhibition of mitochondrial complex IV has shown to affect succinate-cytochrome 
c reductase which leads to secondary loss of complex II-III activity in the ETC 
(Hargreaves, I. P. et al. 2007). Cyanide is a potent complex IV inhibitor but use 
pharmacologically is hindered by the acute cyanide toxicity being attributed to 
inhibition of cytochrome c oxidase (CcOX), the oxygen-reducing component of 
mitochondrial electron transport (Leavesley, H. B. et al. 2008). 
 
A paper published in 2019 (Yamashita et al., 2019) showed the novel 
arylamadine T-2307 exhibited in vitro antifungal properties against pathogens. 
T-2307 inhibited respiration of yeast cell isolates in a dose-dependent manner. 
Complexes III and IV were inhibited in both S. cerevisiae and C. albicans so this 
would suggest that the T-2307 would act similarly with C. glabrata. It also 
suggested that T-2307 has little effect on bovine respiratory complexes 






1.7 Aim of study 
 
The role of complex II inhibitors such as TTFA has been well established but the 
need for a less toxic alternative which can be used safely in mammalian cells is 
needed. The aim of this study is to see if LND has significant anti-fungal 
properties on C. glabrata clinical isolates. It will be measured against 
comparative potent complex II inhibitor TTFA alongside a closely related 
comparative species S. cerevisiae due to the wide array of laboratory strains 
available. The specific objectives of the anti-fungal analysis will be LND’s effect 
on SDH activity, cell viability, growth cycle and biofilm formation. Once 
examined, the discussion will aim to investigate any potential mechanisms of C. 





2. Materials and Methods 
 
2.1 Drug concentrations 
 
LND (MW 321.2g/mol) was prepared by adding 2mL of DMSO (>99.7% assay 
percent range) to a vial of 50mg LND to produce a final concentration of 
77.8mM. The LND final concentration was aliquoted into 200µL aliquots and 
stored in -10oC. Tocris were the supplier used when ordering LND. 
 
TTFA (MW 222.18g/mol) was prepared by adding 10mL of ethanol (>99% assay 
percent range) to a 25mL falcon tube containing 333.27mg TTFA to produce a 
final concentration of 150mM. The TTFA final concentration was aliquoted into 
1mL aliquots and stored in -10oC. If possible, it is advisable to prepare and use 
solutions on the same day. Upon opening of a vial, allow the vial of TTFA to 
equilibrate to room temperature for at least 1 hour. Thermo Fisher Scientific 
were the supplier used when ordering TTFA. 
 
2.2 Analysis of yeast cell growth 
 
2.2.1 Growth curve assay 
 
5mL YPD medium was placed into each test tube that is required and using an 
inoculation loop, the loop was passed through a Bunsen burner to ensure that 




colony of a maintenance plate and placed into the 5mL YPD medium. This was 
repeated for each strain required. All test tubes were placed on a rotary shaker 
at 180 RPM at a temperature of 30oC. Approximately 14-18 hours later, OD600 
0.2 of overnight culture of each strain was placed into 1mL of sterile RPMI 1640 
media in each well of a Greiner 24 well plate (RPMI media to be used to ensure 
conditions replicate the physiological conditions of glucose levels in mammalian 
blood rather than nutritionally rich media such as YPD). 778 M LND, 0.5mM - 
1.5mM TTFA, 1% DMSO and 1% ethanol were pipetted into the necessary 
wells. Triplicate repeats were prepared along with a contamination control 
(RPMI only). The 24 well plate was measured for 24 hours (TTFA) or 40 hours 
(LND) using a BMG LabTech SPECTROstar nano plate reader (Table 1). 
Analysis of growth curve data was analysed by using the MARS software. 
 
Table 1. Measurement settings on the BMG LabTech SPECTROstar nano. 
Excitation  600nm  
Cycle time  360 seconds  
Shaking frequency   400 RPM  
Shaking Mode  8-minute linear shake followed by double orbital shaking  
Temperature   30°C  
Positioning Delay  0.5 seconds  
 
2.2.2 Doubling times (Td) ½  
 
Using growth curve data from MARS software, exponential growth rates were 




log of the number of cells at time zero (t0), which equals the growth rate 
constant multiplied by the time interval: µ = ( (log10 N - log10 N0) 2.303) / (t - t0). 
 
2.3 Tetrazolium blue chloride (BT) assay 
 
For analysis of Succinate dehydrogenase activity of C. glabrata with complex II 
inhibitors TTFA and LND, the reagent Tetrazolium blue chloride is an 
appropriate assay. The BT assay measures cell proliferation by reduction of the 
tetrazolium salt, BT (3,3′-(3,3′-Dimethoxy[1,1′-biphenyl]-4,4′-diyl)-bis(2,5-
diphenyl-2H-tetrazolium) dichloride). This tetrazolium salt produces a blue 
coloration in the cells as they form a formazan product via succinate 
dehydrogenase.  
 
Overnight culture of CG2509 cells used in the experiment were cultivated in 
5mL YPD medium at 30oC on a rotary shaker at 180 RPM for 24 hours. 0.1 
OD600 of CG2509 was pipetted into 3 Eppendorf tubes and labelled ‘WT’, 
‘778µM LND’ and ‘1.5mM TTFA’. All tubes were centrifuged at 11600 x g for 2 
minutes and the supernatant removed. 1mL of RPMI-1640 medium was added 
to each Eppendorf tube and the pellet was resuspended after vortexing to 
ensure the cell pellet was completely resuspended. 1.5mM TTFA and 778µM 
LND were pipetted into their designated wells and a 1mL of cell free control 
medium containing RPMI-1640 was prepared alongside. All 4 Eppendorf tubes 
were incubated at 22oc for 90 minutes. The cells (500µl) were mixed with 250µl 




To each Eppendorf tube, 500µl of Propan-2-ol containing 0.04 HCl was added 
and the solution was vortexed at the highest speed (10) for 2 minutes. The 
acidity ensured that the cell walls lyse and the BT-formazan which is contained 
with the cells were released into the solution. Each Eppendorf tube was then 
centrifuged at 11600 x g for 2 minutes to allow for the cells to form a pellet at the 
bottom of the tube and for the dye to remain in the supernatant. The 
supernatant was pipetted into a 96-well plate and the absorbance of the 
supernatants were measured at 570nm wavelength against a cell-free RPMI-
1640 medium control.  
 
2.4 Cell viability assay 
 
The strain CG2509 was grown in YPD overnight under standard growth 
conditions. A serial dilution of the overnight culture was performed and cells 
were counted under microscopy until ~2000 cells were present in 10L of 
culture. 10L of culture was then pipetted onto fresh YPD plates in technical 
triplicates of the following conditions: YPD (WT control), YPD+ 1mM TTFA, 
YPD+ 778M LND, YPD + 1% DMSO (solvent control) and YPD + 1% ethanol 
(solvent control). After 72 hours hours of incubation at 30oC, colony formation 









2.5 Respirometry  
 
2.5.1 Respiration profiles of C. glabrata clinical isolates 
 
The determination of oxygen consumption and capacity of each C. glabrata 
clinical isolate was performed using an O2k Oxygraph (Oroboros) high 
resolution respirometer in order to first get a respiratory profile. A 2ml 
suspension of the cells grown in YPD overnight containing approximately 1 
million cells per mL was transferred into both chambers. A 20-minute period of 
cellular routine respiration was allowed to reflect the metabolic activity under cell 
culture conditions. 8μl of 50mM Triethyltin Bromide (TET) was added to each 
chamber resulting in the leak of respiration caused by compensation for the 
proton leak after inhibition of ATP synthase. Following the leak 2μl of 12mM 
FCCP (mitochondrial oxidative phosphorylation uncoupler) was added to each 
chamber to uncouple the electron transport chain from the oxidative 
phosphorylation system through interference of the proton gradient. Finally, 2μl 
of 20mM Antimycin A was added to each chamber inhibiting respiration through 
inhibition of complex I and II of the electron transport system. 
 
2.5.2 Respiration profile of C. glabrata with LND titration 
 
The determination of oxygen consumption and capacity of each C. glabrata 
clinical isolate was performed using an O2k Oxygraph (Oroboros) high 
resolution respirometer in order to first get a respiratory profile. A 2ml 
suspension of the cells grown in YPD overnight containing approximately 1 




cellular routine respiration was allowed to reflect the metabolic activity under cell 
culture conditions. 10μl titrations of LND were added (0.389mM to final 
concentration of 2.723mM) once the trace of the graph had begun to plateau. 
Finally, 2μl of 20mM Antimycin A was added to each chamber to inhibit 
respiration through inhibition of complex I and II of the electron transport system 
in order to measure NMR. 
 
2.5.3 Respiration profile of C. glabrata with Flavone and LND titrations 
 
The determination of oxygen consumption and capacity of each C. glabrata 
clinical isolate was performed using an O2k Oxygraph (Oroboros) high 
resolution respirometer in order to first get a respiratory profile. A 2ml 
suspension of the cells grown in YPD overnight containing approximately 1 
million cells per mL was transferred into both chambers. A 20-minute period of 
cellular routine respiration was allowed to reflect the metabolic activity under cell 
culture conditions. 1 titration of 10µM Flavone was added and 3 further titrations 
of LND (0.389mM to final concentration of 1.167mM) once the trace of the graph 
had begun to plateau. Finally, 2μl of 20mM Antimycin A was added to each 
chamber inhibiting respiration through inhibition of complex I and II of the 








2.6 Crystal violet staining analysis of C. glabrata biofilm 
 
2.6.1 Growing the biofilm 
 
Overnight culture of CG2509 cells used in the experiment were cultivated in 
5mL YPD medium at 30oC on a rotary shaker at 180 RPM for 24 hours. 100µL 
of the overnight culture was added to each well in a 96 well plate. Wells were 
prepared in technical triplicates with the following conditions: YPD (cell free 
control), YPD + 1mM TTFA, YPD + 778M LND, YPD + 1% DMSO (solvent 
control) and YPD + 1% ethanol (solvent control). The 96 well plate was 
incubated for 48 hours at 37oC. 
 
2.6.2 Staining the biofilm 
 
To note, crystal violet is toxic and stains very strongly so ensure goggles, gloves 
and laboratory coats are worn at all times when staining with CV. 
 
After incubation, cells were discarded by turning and shaking out the YPD 
medium. The plate was submerged carefully into a tub of water and gently 
shaken. This was repeated for a second time. Shaking allowed for removal of 
cells which were not attached and also for remaining medium that may have 
been background staining to be kept to a minimum. 125L of a 0.1% solution of 
crystal violet was added to each well of the 96 well plate. The 96 well plate was 
incubated at room temperature for 15 minutes. The plate was rinsed 4 times 
with water by submerging as before in a tub of water and shaking carefully. 




paper towels to remove any excess dye. The plate was turned upside down and 
allow to dry for 24 hours. 
 
2.6.3 Quantifying the biofilm 
 
125L of 30% acetic acid was added in water to each well of the 96 well plate to 
ensure the CV solubilized. The plate was incubated at room temperature for 15 
minutes. 125L of the solubilized CV was transferred to a new 96 well plate and 
the absorbance values were read in a plate reader at 550nm. The 30% acetic 
acid in water was used as a control. 
 
2.7 Flow cytometry analysis of Cellular H2O2 production 
 
3mL overnights were inoculated to OD600 0.1 and incubated with the 
fluorescent indicator dye H2DCF-DA (final concentration 5 µg/ml) for 24 hours in 
a SpectroStar plate reader. ROS production was analysed in triplicate, with an 
additional culture per strain acting as an undyed control. Cells were grown in a 
plate reader to measure their growth and ensure that all strains had undergone 
diauxic shift. After 24h of growth, 2.5µl of each culture was suspended in 500µl 
PBS (pH 7.4), stained with propidium iodide (PI; final concentration 2 µg/ml), 
and assessed for ROS production using a BD Accuri™ C6 Plus flow cytometer. 
10000 cells per sample were analysed. Cells were classified into one of four 
groups using a PI-only WT positive control heated for 5 min at 80oC (Figure 6.). 
The proportion of high ROS cells reported corresponds to the proportion of cells 





Figure 6. Classification of cell types according to H2DCF-DA and PI signal 
characteristics. Cells were classified using a quadrant placed around a positive 
control group of WT cells dyed with PI and heated at 80oC. Cells with a PI signal 
greater than the lowest signal observed in the positive control were classified as 
necrotic, and those with a H2DCF-DA signal greater than the highest signal 
observed in the group were classified as high ROS. 
 
2.8 Preparing transformants for lacZ reporter assays  
 
2.8.1 Preparation of the plasmid transformation for the S. cerevisiae TCA 
mutants 
 
This protocol allowed for the insertion of plasmids to express CIT2-lacZ tagged 
proteins within the S. cerevisiae strains used in this study. Cells were grown 
overnight in YPD under standard growth conditions. 400l of the cell culture was 
pipetted into an Eppendorf tube and incubated at 30oC for 4 hours to ensure the 
cells are in log phase. Cells were centrifuged at 4000 RPM for 5 minutes. The 
supernatant was removed from the pellet, which was then washed and 
resuspended in 400L of sterile water. 100L of the suspension was transferred 




plasmid. The Eppendorf tubes were then centrifuged at 4000RPM for 30 
seconds and the supernatant was removed. Into each of the Eppendorf tubes, 
360l of the master mix (prepared by the ingredient list shown in table 2). 
 
Table 2. The reagent list to prepare a master mix 
Reagents 1 transformation 
PEG 3500 50% w/v 240L 
LiAc 1.0 M 36L 
Boiled SS-carrier DNA 10L + 40L sterile water 




The cells were bathed in a water bath for 40 minutes at 42oC then centrifuged at 
10000RPM for 30 seconds and the supernatant was removed. The cells were 
re-suspended in 200L of sterile water. The cells were plated on the necessary 
selective plates (SD-URA agar plates) and incubated at room 30oC for 3-5 days, 









2.8.2 BY4741 strains used for transforming with CIT2-lacZ plasmid 
 
Table 3. S. cerevisiae strains used from the BY4741 mutant library 













2.9 β-galactosidase liquid culture assay 
 
Cells transformed with a lacZ plasmid were grown in SD-URA overnight and 
then sub cultured to OD600 0.1. Triplicate replicates were prepared with the 
following conditions: 778M LND, no drug and no cells (control). All of the cells 
were allowed to grow to for 24 hours. In microcentrifuge tubes. 100L of culture 
was added to 500L of Z buffer (reagent list as seen in table 4) and incubated at 




hand to start the reaction. After 12 hours, 400L of 1.5M Na2CO3 was added to 
halt the reaction. Samples were centrifuged for 1 minute at 10,000RPM and the 
absorbance measured at 420nm and 550nm. 
 
Table 4. Ingredient list for Z-buffer and ONPG 
Reagent Description 
Z buffer 60mM Na2HPO4, 40mM NaH2PO4, 10mM KCl, 1mM 
Mg2SO4, 50mM -merceaptoethanol (added directly 
before use before use.) 
ONPG 4mg/ml dissolved in water (prepared and used in one 
day due to sensitivity to light). 
 
2.10 PyMoL analysis of the LSC2 beta subunit 
 
2.10.1 Screening species for fungal specific residues in LSC2 
 
The origin sequence of the beta subunit LSC2 was gathered from the most 
common fungal species from the NCBI protein database 
(https://www.ncbi.nlm.nih.gov/protein/) along with the equivalent found in H. 
sapiens and M. Musculus. Sequences were compared using Clustal Omega 







2.10.2 iTasser structural predictions of LSC2 
 
From the origin sequence gathered from the NCBI protein bank in section 
2.10.1, the sequences were uploaded to the iTasser online service provided by 
the Zhang lab (https://zhanglab.ccmb.med.umich.edu/I-TASSER/annotation/) 
and a predicted structure of the LSC2 enzyme for both S. cerevisiae and H. 
sapiens were generated. The PyMoL predicted structure files (.pdb) were 
downloaded.  
2.10.3 Visualising the fungal specific region on LSC2 with PyMoL 
 
By using PyMoL software, it was made possible to overlay the predicted 
structural LSC2 enzymes by opening both .pdb files in PyMoL. The fungal 
specific tyrosine was highlighted red by utilsing the sequence mode. The 
residue site was found by entering sequence mode, right clicking the Tryosine 
and clicking the colour palette. The structures were overlayed by clicking display 
and then clicking overlay. 
2.10.4 Modifying the fungal specific region on LSC with PyMoL  
 
By zooming into the fungal specific region on PyMoL and selecting the region, 
the default ribbon structure was changed to stick form view. By selecting the 
residue and entering builder mode, the Tyrosine was replaced with different 







The project sought to investigate and compare the respiration characterisitcs in 
both a series of clinical isolates of the human fungal pathogen C. glabrata and 
S.cerevisiae laboratory strains. In addition, a series of assays were conducted 
to determine the effects of inhibition of SDH in both C. glabrata and S. 
cerevisiae. It was examined whether SHD inhibition, or loss of TCA or glyoxylate 
cycle functionality, led to respiratory stress and reduced viability. These 
experiments were aimed to increase our understanding as to whether SDH and 
mitochondrial metabolism are suitable targets for anti-fungal drug development. 
 
3.1 The effects of LND addition on C. glabrata growth  
 
Growth assays were performed over a period of 40 hours comparing control and 
LND treated cells. Treatment with DMSO (solvent control) led to inhibition of C. 
glabrata growth (Figure 7B) that was also observed in LND treated cells (Figure 
7A). However LND treatment led to pronounced cell aggregation as seen in the 
widening and eratic nature of the curve during (Figure 7A). The aggregation was 
observed in all isolates (Figure 7 ia representative graph, see appendix 1 for the 










Figure 7. Growth assay of C. glabrata clinical isolate with 778 M LND and 1% 
DMSO in RPMI media over 40 hours. (A) Clinical isolate CG2509 growth 
comparison with LND treated cells. (B) Clinical isolate CG2509 growth 
comparison with DMSO treated cells. 
 
To complete the growth analysis, doubling times were calculated for all four 
clinical isolates when with LND treated cells compared to WT control cultures 
containing the solvent (Figure 8). LND treatment led to a significant increase in 
doubling time in three out of the four clinical isolates, with the fourth showing a 
similar trend. These data confirm that LND treatment leads to growth inhibition. 


































































Figure 8. Doubling times of C. glabrata clinical isolates were measured and 
represent the slowing effects of LND on the cells ability to grow during 
exponential phase. The statistical analysis of the doubling times for CG30261 
were non significant, CG2509 (P < 0.005), CG027884 (P < 0.05) and CG028987 
(P<0.05). 
3.2 Effects of TTFA on C. glabrata growth  
 
Having assessed the effects of LND treatment on C. glabrata, it led to testing 
whether similar effects were observed in the presences of the potent complex II 
inhibitor TTFA. TTFA also led to inhibitory effects on the growth of C.glabrata 
(Figure 9A) at all three concentrations. The ethanol solvent control confirmed 
that ethanol alone was not causing this reduction in growth (Figure 9B). 
Representative graphs are presented. Together these data sets suggest that 


















Figure 9. Growth assay of CG2509 with varying concentrations (0.5mM, 1mM 
and 1.5mM) of TTFA and upto 1% ethanol in RPMI media over 24 hours. (A) 
WT growth comparison with TTFA treated cells. (B) WT growth comparison with 
ethanol treated cells. 
3.3 Effects of LND treatment on SDH activity in C. 
glabrata  
 
Having seen that LND had a significant effect on C. glabrata clinical isolates, it 
was important to determine if the drug was inhibiting SDH activity. This can be 
achieved by assaying reduction of the tetrazolium salt Nitroblue tetrazolium (BT) 
and observing production an insoluble product that can be measured at an OD 
of 570nm using a spectrophotometer. The experiment confirmed that exposure 
of C. glabrata cells to either LND or the well characterised SDH inhibitor 







































































prevented BT reduction (Figure 10). This suggests that LND acts as an SHD 
inhibitor in C. glabrata. 
 
Figure 10. The strain CG2509 was grown in YPD overnight under standard 
growth conditions along then inoculated to OD600 0.1 with technical triplicates of 
YPD, YPD+ 1mM TTFA and YPD+ 778M LND. After 24 hours, NBT was 
added to each to measure the reduction of the tetrazolium salt. The reaction 
was halted and absorbance value were taken at OD 570nm using a 
spectrophometer. The BT asborbance value represent inhibitory effects of TTFA 
and LND on the ability of C. glabrata to proliferate by measurement of the 
reduction of tetrazolium salt. 
 
3.4 Effects of SDH inhibition on C. glabrata viability  
 
After confirmation that LND was indeed inhibiting the SDH enzyme on par with 
the highly potent complex II inhibitor (TTFA), it led to determining whether 
inhibition of SHD activity led to a reduction in viability in C. glabrata clinical 
isolates. To achieve this, the data suggests that inhibition of SDH with either 
LND or TTFA led to a reduction in cell viability relative to their solvent controls 





Figure 11. The strain CG2509 was grown in YPD overnight under standard 
growth conditions. A serial dilution of the overnight culture was performed until 
~2000 cells were pipetted onto YPD plates in technical triplicates of the 
following conditions: YPD (WT control), YPD+ 1mM TTFA, YPD+ 778M LND, 
YPD + 1% DMSO (solvent control) and YPD + 1% ethanol (solvent control). 
After 72 hours hours of incubation, colony formation was counted via 
microscopy. Inhibitory effects of TTFA and LND on the ability of C. glabrata to 
produce viable colonies on a YPD petri dish over 4 incubating days. One-way 
anova analysis was performed (***P<0.005, ****P<0.0005). 
  
3.5 Effects of SHD inhibition on Respiration in C. 
glabrata clinical isolates 
 
3.5.1 Respiratory profiles of the C. glabrata clinical 
isolates 
 
In order to measure how the respiration of the C. glabrata clinical isolates coped 




crucial to characterise C. glabrata respiratory profiles in each of the four clinical 
isolates.  
 
In order to gather the data the following protocol was performed. Routine 
respiration was obtained before the introduction of the ATPase inhibitor 
triethyltin bromide (TET) which induces a build up of protons within the into the 
membrane space and  inhibition or respiration linked to ATP produciton. Oxygen 
consumption that occurs following TET application requires non-ATP synthase 
associated proton movement across the inner mitochondrial membrane and is 
referred to as LEAK respiration. The difference between LEAK and routine 
respiration suggested how coupled ATP synthesis is linked to the ETC. FCCP 
acts as an uncoupler by making pores in the membrane, in a reversible manner, 
allowing protons to flow through the pore. This caused a dissipation of the 
membrane potential which in turn allows maximum movement of electrons 
through the ETC. Measurement following FCCP addition therefore referred to 
the maximum respiration potential. This maximum value provides an insight into 
just how fast this electron transport chain may go and to what extent it is 
suppressed. Following FCCP addition, a measurement was then taken after 
introduction of the irreversible Complex III inhibitor Antimycin A. Inhibition of 
complex III stops electrons flowing through the chain past complex III and 
prevents all mitochondrial associated oxygen consumption. The difference 
between routine and the value after adding Antimycin A shows what level of 
oxygen consumption due to mitochondrial respiration. Any residual oxygen 
consumption following Antimycin addition represented non-mitochondria O2 




cells have upregulated other oxygen consuming processes such as fatty acid 
beta oxidation in the peroxisomal compartment. By producing respiratory 
profiles for all four clinical isolates, it highlighted how much variance there is 
amongst clinical isolates. The routine respiration for CG027884 (Figure 12B) is 
abnormally high along with the leak (proton) respiration compared to the other 
clinical isolates despite all isolates sharing similar MAX (maximum respiration). 
All isolates produce NMR once Antimycin A impaired the mitochondrial function. 
As the respiratory profiles were not statistically analysed, it can be not said that 
this fluctuation across the isolates happened by chance. For future work, it 
would be beneficial to repeat. Having generated the respiratory profiles, it 
allowed for respiratory experiments on LND treated cells to see if LND has an 
effect on NMR once complex II is inhibited or whether C. glabrata can overcome 








A  B  
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Figure 12. Respirometry profiles of overnight cultures (grown for 18 hours) of C. 
glabrata clinical isolates during stationary phase. Cells were left to reach a 
stable ROUTINE before adding 50mM TET to represent the LEAK, 12mM FCCP 








































































































































































































added to represent the NMR. (A-D) Bar graphs show the similarity of all isolates 
respiratry profile whereby all have a routine which is slightly higher than the 
LEAK. All four show the highest value in the MAX and a very small NMR. (E) 
CG2509 is shown an example of a respirometry profile taken in DataLab. 
3.5.2 Effects of LND on the C. glabrata respiration 
  
The respirometry analysis of C. glabrata LND was performed in order to see if 
loss of SDH activity would lead to respiratory failure. Into the respirometers 
chambers of 2mL YPD, ~1 million cells per mL were added to each chamber 
after using a cell counter to dilute the overnight culture accordingly. Cells were 
left to reach routine before titrating DMSO (0.5% to a final concentration of 
3.5%) into chamber A and LND (0.389mM to a final concentration of 2.723mM) 
into chamber B, titrating again once the traces began to reach routine. The 
respirometry analysis (Figure 13) shows an initial drop once drug or solvent is 
added, this is to be considered irrelevant since this only occurring due to the 
injected liquid and consequently Oxygen into the chamber. The important 
finding is once the trace returns (after injection of drug/solvent) and overshoots 
the routine respiration. In the case of LND, the overshooting is larger than that 
of ethanol which suggests a transient uncoupling (as happens with FCCP in 
Figure 12 which is represented as MAX). It confidently shows that SDH 
inhibition doesn’t inhibit respiration and that complex II is not being engaged in 
the electron transport chain. The effects of SDH inhibition on growth and viability 








Figure 13. Respirometry DataLab graphs of overnight cultures (grown for 18 
hours) of C. glabrata during stationary phase. Cells in both chambers were left 
to reach a stable ROUTINE before adding drugs and solvents. (A) Adding 7 
titrations of DMSO (0.5% to a final concentration of 3.5%) as a solvent control. 
Adding 20mM of Antimycin A reduced mitochondrial respiration completely. Any 
remaining O2 flux represents NMR. (B) Adding 7 titrations LND (0.389mM to a 
final concentration of 2.723mM) suggests a transient uncoupling but the cells 
were able to recover quickly. Finally, adding 20mM of Antimycin A reduced 
mitochondrial respiration completely. Any remaining O2 flux represents NMR 
which was higher than that of solvent only. 
3.5.3 Effects of NADH dehydogenase and LND inhibition 
on C. glabrata respiration 
 
 
C. glabrata does not have a complex I but it does have mitochondrial external 
NADH dehydrogenase (NDE1 and NDE2) and a NADH Dehydrogenase Internal 
(NDI1). Flavone, which is a specific inhibitor of the S. cerevisiae NDI1 has 
shown to inhibit almost completely NADH oxidase and NADH‐UQ1 reductase 
activities of NDI1 (Kitajima-Ihara and Yagi, 1998) so was used to test to see if 
by inhibiting firstly NDI1, that the effects of inhibiting II would amplify the effects 
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produced after administration so suggests further transient uncoupling. The cells 
were able to overcome the temporary disruptions from both drugs administered.  
This further suggests that SDH inhibition doesn’t inhibit respiration and that 





Figure 14. Respirometry DataLab graphs of overnight cultures (grown for 18 
hours) of C. glabrata during stationary phase. Cells in both chambers were left 
to reach a stable ROUTINE before adding drugs and solvents. (A) Adding 4 
titrations of DMSO (0.5% t to final concentration of 2.0%) as a solvent control 
showed minor disruptions to the ETC membrane. Finally, adding 20mM of 
Antimycin A reduced mitochondrial respiration completely. Any remaining O2 
flux represents NMR. (B) Adding 1 titration of 10µM Flavone causes a huge 
membrane disruption and 3 further titrations of LND (0.389mM to final 
concentration of 1.167mM) caused a transient uncoupling but the cells were 
able to recover quickly. Finally, adding 20mM of Antimycin A reduced 
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C. glabrata cells can form a biofilm and this is a major determinant of its 
virulence. Biofilms are naturally multi-drug resistant and represent a clinical 
problem. To determine if inhibition of SDH could inhibit biofilm, overnight culture 
of CG2509 were grown for 18 hours. Overnights were diluted to OD600 0.1 in 
fresh media and 100L of the culture was placed into a 96 well plate. Triplicate 
repeats with the following conditions were pipetted: WT control, 1mM TTFA, 
778M LND, 1% DMSO (solvent control) and 1% ethanol (solvent control). After 
2 days of incubation (30oC) to allow growth of a biofilm, the mature biofilm was 
assessed by using crystal violet which stains the biofilm matrix material. It was 
observed that both TTFA and LND led to a significant reduction in C. glabrata 
biofilm growth. TTFA showed more potent inhibitory effects than LND by 
reducing the biofilm by ~2/3’s (P < 0.005) whilst LND reduced biofilm formation 





Figure 15. Crystal violet staining representing the inhibitory effects of LND and 
TTFA on C. glabrata biofilm formation at maturity (48 hours at 30oC). Data is 
from triplicate repeats with the following conditions were pipetted: WT control, 
1mM TTFA, 778M LND, 1% DMSO (solvent control) and 1% ethanol (solvent 
control) after 2 days of incubation (30oC) to allow growth of a biofilm. Error bars 
based on standard deviation which was calculated from triplicate values (n=3). 











3.7 Effects of SDH inhibition on ROS accumulation 
 
3.7.1 Effects of SDH inhibition on ROS accumulation in C. glabrata cells 
 
Flow cytometry analysis of the C. glabrata clinical isolates treated with LND was 
performed to see if ROS accumulated following SDH inhibition. The dye 
H2DCFDA is a chemically reduced form of fluorescein used as an indicator for 
reactive oxygen species (ROS). Upon cleavage of the acetate groups by 
intracellular esterases and oxidation, the nonfluorescent H2DCFDA is converted 
to the highly fluorescent 2',7'-dichlorofluorescein (DCF). Necrotic cells were 
assessed by the addition of Propidium Iodide (PI). PI is a red-fluorescent cell 
viability dye which is excluded from live cells with intact membranes but 
penetrates dead or damaged cells and binds to DNA and RNA by intercalating 
between the bases. High ROS cells appear in the bottom right quadrant (Figure 
16A-C) and high necrotic cells appear in the top left quadrant. PI-A Flow 
cytometry analysis showed that both the solvent control and LND produced only 
0.1% high ROS cells compared to WT. A small increase of 2.4% necrotic cells in 
LND treated cells compared to WT and this was not from the solvent alone. In 
the future, it would be crucial to repeat this experiment in order to statistically 
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Figure 16. Clinical isolate CG2509 was grown in glucose overnight, diluted to 
OD600 0.1 in RPMI and 5mg/mL H2DCF-DA added except for the control. A 1% 
DMSO control, a cell free control and a 778M LND sample was prepared 
alongside. 2.44mg/mL PI dye was also added which represents necrotic cells. 
This led to the assessment of both necrosis and ROS production by flow 
cytometry.Flow cytometry anaylsis showed no difference in levels of ROS 
production in LND treated C. glabrata cells compared to WT. (A) WT (B) LND 
0.1 % of ROS (C) DMSO 0.1% of ROS. 
 
3.7.2 Effects of SDH inhibition in TCA and glyoxylate cycle mutant S. 
cerevisiae cells  
 
Having observed that SDH is not operating within the ETC in C. glabrata, it was 




challenged in TCA and glyoxylate cycles. A list of the most important enzymes 
involved within both the glyoxylate cycle and the TCA were chosen (Figure 17). 
 
 
Figure 17. A schematic highlighting the important enzymes involved in each 
step of the glyoxylate and TCA cycle. 
 
Once the panel of mutants was generated, these were located within the S. 
cerevesiae BY4741 mutant library and streaked out onto fresh YPD plates. The 
loss of encoded idh2 and lsc2, fum1 and mdh1 led to synthetic growth 
effects when cells were grown in the presence of TTFA. The experiment was 




extent of the inhibitory effects. The strains that did not produce produce 
observable effects were cit1, aco1, kgd1 and sdh2 (see appendix 2). TTFA 
treated cells led to a very pronounced effect in stationary phase that may 





















































































































































































Figure 18. Growth assays of S. Cerevisiae which shows loss of respiration 
during the stationary phase of  WT and TCA mutants with 1mM TTFA in YPD 
media over 24 hours. (A)WT (B)Δidh2 (C)Δlsc1 (D)Δlsc2 (E)Δfum1 (F)Δmdh1. 
 
 
SDH inhibition does not appear to lead to ROS accumulation in C. glabrata cells 
(Figure 16). This led to investigate whether abrogation of TCA and glyoxylate 
cycle would lead to ROS accumulation in S. cerevisiae. To achieve this, the use 
of the readily available mutant library was made available. With the loss of SDH 
activity, it led to experimenting with laboratory strains of S. cerevisiae and single 
TCA knockout mutants which represented each of the major TCA enzymes. Of 
the enzymes, idh2 and sdh2 were the highest producing ROS mutants.  A 
strain lacking COX4, a core component of complex IV whose loss has been 
shown to lead to ROS accumulation (Leadsam et al., 2014) was used as a 























































Figure 19. Strains with a single knockout of one of the key TCA enzymes were 
grown in glucose overnight, diluted to OD600 0.1 in RPMI and 5mg/mL H2DCF-
DA added except for the control. 2.44mg/mL PI dye was also added which 
represents necrotic cells. This led to the assessment of both necrosis and ROS 
production by flow cytometry. (A) All of the main TCA enzyme mutants shown in 
a bar graph whereby sdh2 and idh2 prove to be the biggest ROS producing 




















































3.8 Linking loss of SDH activity to mitochondrial stress 
and retrograde signalling  
 
3.8.1 Measuring the effects of LND on the WT4741 and sdh2 CIT2 
promoter as an indicator of the retrograde signalling  
 
This assay measured CIT2 levels which is an indicator of retrograde signalling 
in response to mitochondrial stress. As it is already suggested that SDH 
inhibition doesn’t affect respiration, it led to investigating whether loss of SDH 
leads to retrograde signalling. The assay showed activation at certain points 
along the cycle. Having seen how LND was showing anti-fungal properties with 
cell viability and biofilm reduction but also resisting permanent respiration failure 
with a dysfunctional mitochondria, it led to seeing if LND was causing an 
activation of the CIT2 promoter (indicates an increase in glyoxylate cycle 
signalling). The ONPG assay showed that LND treated cells (P < 0.0005) 
produced ~4 fold increase in CIT2 levels compared to WT. It also showed that 
the sdh2 gained (P < 0.0005) ~2 fold increase in CIT2 levels when 





Figure 20. An Overnight culture of WT4741 and sdh2 transformed with a lacZ 
plasmid were grown in SD-URA overnight (in order to preserve the plasmid and 
ensure cross contamination of species which may thrive in glucose medium) 
and then sub cultured to OD600 0.1. Triplicate replicates were prepared with the 
following conditions: 778M LND, no drug and no cells (control). After a further 
24 hours of incubation, the ONPG assay was initiated by addition of ONPG and 
halted after 24 hours. CIT2 has served as a prototypical readout for the yeast 
retrograde response. The ONPG assay allows colorimetric measuring of the 
activity of the CIT2 promoter. ONPG provided the substrate for measuring the -
galactosidase activity which is the enzyme encoded by the lac-Z gene, which is 
being driven by the CIT2 promoter. This allowed for all the single knockout 
transformants with a CIT2-lacz target to test whether LND was causing an 
upregulation of the RTG in response to a faulty TCA cycle. ONPG assay 
comparison of WT and sdh2 when treated with LND for 12 hours. Both WT and 
sdh2 show a strong correlation between the application of LND and the 
increase in LacZ activity. 
3.8.2 Combinational effects of SDH inhibition and TCA/glyoxylate cycle 
inhibition on retrograde signalling in Cerevisiae  
 
Treatment of S. cerevisiae cells with LND led to activation of the CIT2 promoter 
activity, indicating that retrograde signalling had been activated. This led to see 
whether this effect would be modulated when TCA and glyoxylate cycles were 




particular steps in the TCA and glyoxylate cycles served as triggers for 
retrograde signalling. After seeing how LND seemed to sustain activation of the 
glyoxylate cycle through the elevated CIT2 levels in the ONPG assay (CIT2 has 
served as a prototypical readout for the yeast retrograde response), it was worth 
investigating further to see if there was a specific enzyme in either the TCA or 
glyoxylate cycle which could show sensitivity to LND. This could lead to future 
combinational drug therapy. The ONPG assay allowed for all the single 
knockout transformants with a CIT2-lacz target to test whether LND was 
causing an upregulation of the RTG in response to a faulty TCA cycle. Upon 
administration of LND, all mutants saw an increase in CIT2 levels except for 
icl1 (which is located within the glyoxylate cycle). This suggests that ICL1 has 
an important role within the glyoxylate cycle and ultimately without it, the cells 
would not be able to synthesis the necessary intermediates by utilising other 
carbon sources. In the future, it would be crucial to repeat this experiment to in 






Figure 21. A schematic highlighting the important enzymes involved in each 
step of the glyoxylate and TCA cycle. 
 
Figure 22. An extended ONPG assay comparison of WT and mutants of the 




4. Discussion  
 
Further importance of Succinylation to this project is that it can bring reason as 
to why a complex II inhibitor such as LND and the comparative TTFA differ so 
very much in terms of their response when bound. TTFA when bound elicits an 
inhibitory growth curve (Figure 9A). On the other hand, LND when bound 
mimics the WT until stationary phase when it causes severe aggregation (Figure 
7A). Lysine Succinylation could be the signalling mechanism that allows LND to 
cause global effects within the cell. 
 
4.1 Inhibition of SDH affects growth and viability of C. 
glabrata  
 
Two drugs (TTFA and LND) that are reported to target SDH activity were used 
and tested to see how active the SDH enzyme itself is when treated with 
complex II inhibitors. By measuring how active the SDH enzyme is, this gives 
reassurance that firstly the drug is having an effect on the enzyme and secondly 
how much of an effect LND can produce on the enzyme when bound. The 
reduction of a tetrazolium salt such as Blue Tetrazolium Chloride (BT) is the 
most suitable way by providing substrate for the SDH enzyme and the 
measurement being how much of the tetrazolium salt is being reduced to 
formazan. Both TTFA and LND showed a huge reduction in tetrazolium 
conversion to formazan compared to the wild type. More surprising is that LND 
showed to be a greater inhibitor for this assay to that of the TTFA. This 




but it could be said purely from this one experiment if this temporarily inactive 
SDH enzyme would cause cells to remain viable or not. It is a common mistake 
to take the absorbance values from a colorimetric assay such as this and 
perform a cell viability calculation ((Absorbancesample – Absorbanceblank)/ (Absorbancecontrol 
– Absorbanceblank)x100) and assume this is the true viability percentage of each 
sample. The issue with this is that it does not consider whether the cells may be 
stuck in a mutational cell cycle whereby the cells can perfectly form formazan by 
conversion of tetrazolium, but it would not be able to form colonies, thus it is not 
truly viable. It is not uncommon for cells such as Candida to be very plastic 
when inhibitors are introduced to them and this is something that needs to be 
taken into consideration with this assay.  
 
Coupling the BT assay with the viability assay allows the project to confidently 
state that firstly the drug is having an effect on the SDH enzyme and secondly 
whether the complex II inhibitor is having an effect on viable cells to form 
colonies. If the BT assay was a true representation of viable cells, then it would 
be expected to mirror the results shown in both assays, but this is not the case. 
The BT assay (Figure 10) showed nearly fully diminished SDH activity for both 
LND and TTFA treated cells but this reduction is not seen in the viability assay 
(Figure 11). This suggests that whilst the cells are temporarily disrupted as the 
drugs are bound to complex II, the cells are able to recover from this disruption 
but not completely. The question that arose from the coupled experiment is what 
mechanisms were occurring to allow for the cells to partially overcome this 
mitochondrial dysfunction. It has already been shown that during the cellular 




50% as well as glyoxylate related enzyme activation such as ICL1 and MLS. 
This selection allows cells to reveal the mechanism of their higher viability as 
caused by shunting of complete Krebs cycle by glyoxylate cycle, with a 
concomitant increased rate of the most efficient energy source, namely 
succinate formation and oxidation (Samokhvalov, Ignatov and Kondrashova, 
2004). 
 
The C. glabrata clinical isolates showed a lot of variation in their growth curves. 
Isolates CG30261 and CG027884 produced a curve which suggests inhibitory 
effects with LND but CG2509 and CG028987 produced a growth curve which 
that mimicked the WT. This highlights the unpredictable results which can come 
from using clinical isolate studies (in-vivo) compared to laboratory strains (in-
vitro). As this project uses four clinical isolates which have already shown 
varying genotypic characteristics in the growth assays, there could be potential 
for a significant degree of plasticity, depending upon the genotype and different 
environmental pressures. The solvent control showed that DMSO led to a 
pronounced inhibition of growth in all four clinical isolates, this was also 
observed in the LND treatment and so growth reduction may be due to DMSO 
alone. Statistical analysis was not performed so it cannot be said whether this 
happened purely by. It would have also been ideal to repeat the same 
experiment at varying temperatures in order to see if there was any difference in 






For all four isolates, the trace of the curve as shown by the increased peaks and 
troughs becoming wider could suggest aggregation and this is not seen in the 
solvent control, so it suggests it is solely from LND. The growth curves were not 
statistically analysed and the data for each clinical isolates technical repeats are 
no longer available so it cannot be said that this did not occur purely by chance. 
The result does show that the trace in question was apparent in all four of the 
different clinical isolates treated with LND so a future suggestion would be to 
produce technical repeats of all four clinical isolates to highlight if this could be 
due to noise associated with the equipment and the protocol. Aggregation was 
seen visibly in the cells when they appeared to be growing in clump formation 
and the visible clumping shown consistently in the wells when taking out of the 
plate reader during experiments. This is important as the cell wall appears to 
have been affected if this is to be true, causing cell walls of neighbouring cells to 
stick together and adhesin molecule activity being potentially enabled. As 
mitochondrial function is linked to the aggregation phenotypes (Dhar, R. 2020), 
possibly mitochondrial damage has caused enabling of cell wall integrity 
pathway. As the mitochondria is also involved in lipid maturation, these 
damaged cells may have reduced lipid synthesis that is usually sent to the cell’s 
membrane. The cells maybe sensing this change and responding by an internal 
stress response which in turn would repair the plasma membrane and cause a 






Figure 23. An overview of the cell wall 
 integrity pathway (Philip and Levin, 2001). 
 
The mechanisms behind the cell wall integrity pathway (CWI) (Figure 23) are 
well documented and drugs are already known to have effects along the 
cascade. Caffeine has shown to induce phosphorylation of Mpk1p and was 
accompanied by a negligible activation of its main downstream target, the 
Rlm1p transcription factor. This result was consolidated by the finding that the 
loss of RLM1 had no consequence on the increased resistance of caffeine-
treated cells to zymolyase, indicating that the cell wall modification caused by 
this drug is largely independent of transcriptional activation of Rlm1 upregulated 
genes (Kuranda et al., 2006). 
 
There is literature that links the state of the mitochondria and the changes of the 
cell wall (Xia, M. F. et al. 2019) and this could might explain why this flocculation 




(Hog1p) activation mediates mitochondrial dysfunction and catalase A 
deficiency associated with oxidative stress sensitivity and premature aging of 
inositol phosphosphingolipid phospholipase C (isc1) cells. Downstream of 
Hog1p, Isc1p deficiency activates the CWI pathway. Deletion of the SLT2 gene, 
which encodes for the MAPK of the CWI pathway, was lethal in isc1 cells and 
this mutant strain was hypersensitive to cell wall stress. However, the 
phenotypes of isc1 cells were not associated with cell wall defects. This 
supports a role for Hog1p in the regulation of mitochondrial function and suggest 
that constitutive activation of Hog1p is deleterious for isc1 cells under oxidative 
stress conditions and during chronological aging (Barbosa et al., 2012). 
 
It has also been shown that signalling from the mitochondria to affect the cell 
wall involves ANAC017, a transcription factor important in retrograde signalling 
to the nucleus upon mitochondrial dysfunction (Hu et al., 2016). This work 
provided some insight into a mechanism which could explain both how the cells 
are able to respond to mitochondrial dysfunction but also link the aggregation to 
mitochondrial disruption. 
 
A further experiment that could have been performed to test if there was a link 
between the TCA cycle function and cell wall structure would be to grow TCA 
single deletion mutants to represent a strain with each of the main TCA 
enzymes missing as seen in figure 19A. Once the cells were subcultured to 
OD600 0.1 and the subculture grown to stationary phase, they could be stained 
with Congo red (CR) and Calcofluor white (CFW). The rationale is that the cell 




the construction and stress response of the cell wall and would allow for 
microscopy analysis to view how each strains cell wall looks compared to a wild 
type. By comparing the strains, it would have given a good insight into which 
strain could potentially have the most dependence on when the cell responds to 
stresses. 
 
Rapamycin has also shown to have effects on the TOR (target of rapamycin) 
pathway. TOR controls cell growth in response to nutrient availability and 
inactivation of TOR function by rapamycin or nutrient exhaustion is 
accompanied by triggering various cellular mechanisms aimed at overcoming 
the nutrient stress (Torres et al., 2002). In S. cerevisiae, the protein kinase C 
(PKC)-mediated mitogen-activated protein kinase pathway is regulated by TOR 
function because upon specific Tor1 and Tor2 inhibition by rapamycin, Mpk1 is 
activated rapidly in a process mediated by Sit4 and Tap42. Osmotic stabilization 
of the plasma membrane prevents both Mpk1 activation by rapamycin and the 
growth defect that occurs upon the simultaneous absence of Tor1 and Mpk1 
function, suggesting that TOR inhibition is sensed by the PKC pathway at the 
cell envelope. This process involves activation of cell surface sensors, Rom2, 
and downstream elements of the mitogen-activated protein kinase cascade. 
Rapamycin also induces depolarization of the actin cytoskeleton through the 
TOR proteins, Sit4 and Tap42, in an osmotically suppressible manner. During 
entry into stationary phase, a physiological situation of nutrient depletion, also 
leads to the activation of the PKC pathway, and Mpk1 has shown to be essential 
for viability once cells enter G0 (Torres et al., 2002). As shown by Rapamycin, 




activation of the PKC pathway, Mpk1 seems to be the main drug target and this 
could be where the severe aggregation that LND causes could be potentially 
inducing. In order to have tested this theory, it would have been useful to 
perform a western blot to analyse whether LND treated cells had varying 
difference of band intensity than that of untreated cells. Having seen flocculation 
accumulation, a Western blot analysis would state whether LND alone had 
affected the cell wall by inducing the CWI signalling at the point of the MpK1 
enzyme. 
 
TTFA produced a much cleaner growth curve and shows a very clear inhibitory 
growth curve compared to WT. Solvent control showed that ethanol alone did 
not produce this growth inhibition. TTFA showed very potent inhibitory effects 
(Figure 9A) compared to wild type. This confirmed that complex II when 
disrupted can have significant anti-fungal properties but also that complex II 
inhibitors have very different effects within the cell. Flocculation as seen with 
LND treated cells was not seen with TTFA treated cells or with either DMSO or 
ethanol treated cells, so this confirmed that the flocculation is specific to LND. 
The growth curve which was performed using S. cerevisiae and LND failed due 
to equipment malfunctioning, so it was not possible to show whether this 
flocculation was species specific. For future work, it would be interesting to 






Another growth assay for future work would be to combine LND with N-acetyl-
cysteine (NAC) which is known to salvage ROS and see the time difference 
between cell death of NAC treated and NAC untreated with LND. 
 
4.2 Inhibition of SDH affects C. glabrata biofilm 
formation 
 
C. glabrata biofilms are important as they are the species main form of virulence 
as an opportunist pathogen. The biofilm is utilised as a means of defence 
against both drugs and allow for the compact layer of cells to colonise on 
medical equipment such as tracheostomy tubes or on wounds that a patient 
may have. By reducing the biofilm formation or disrupting a mature biofilm, it 
could hinder the pathogen or at least reduce the opportunity for it to invade an 
immunocompromised patient. 
 
Following the flocculation finding, it was worth investigating if the growth defects 
that occurs from potential cell wall stress could be having a knock-on effect on 
the cells ability to cooperate with neighbouring cells to form a mature biofilm. 
Whether overly induced adhesin molecule synthesis could lead to an increase in 
a biofilm’s structural integrity or whether LND’s apparent cellular disruptions 
could be more inhibitory on a biofilm’s population than its very minimal inhibitory 
effects on a C. glabrata single cell. Upon staining of crystal violet after 2 days of 




glabrata to form a mature biofilm. TTFA has already shown to be a very useful 
in reduction of biofilms in other species such as B.subtilis (Qin et al., 2019).  
 
As C. glabrata utilises the biofilm as its most virulent factor, biofilm reduction is a 
vital anti-fungal property which makes LND a very appealing drug for future 
research as many investors in the healthcare setting such as Doctors and 
Dentists have to overcome biofilm formation regularly among their patients. For 
future work, it would be ideal to repeat the experiment but add LND after 24 
hours of incubation to see how the drug can effect a biofilm which has already 
begun to mature, as previously stated that the C. glabrata biofilm is rich in a 
mesh of both carbohydrates and proteins, this could hinder LNDs ability to reach 
the cells to have its desired effects. This project can only state that LND disrupts 
biofilm formation if administered in the early stages of formation. 
4.3 Inhibition of SDH by LND does not lead to respiratory 
disruption in C. glabrata 
 
The spike after LND is administered during the respirometry analysis (Figure 
13B) represents a transient increase in flow of electrons through the chain. This 
led to investigating whether the SDH inhibition may be causing a reliance upon 
the NADH Dehydrogenase Internal (NDI1) (complex I equivalent in C. glabrata). 
This was ruled out after a combination of Flavone and LND produced transient 





The finding that SDH inhibition does not lead to respiratory disruption was quite 
an interesting and unexpected finding considering how effective it has been 
shown in the BT assay to inhibit the SDH enzyme activity (Figure 10) and how 
reliant both LND and TTFA have shown in literature to produce ROS in DB-1 
melanoma cell line cells (Guo et al., 2016). This could suggest that yeast 
suggests yeast cells have evolved to monitor metabolism at these points in the 
mitochondria, to try and re-wire metabolism to remain viable and when 
disrupted. As in the case of LND, markers of poor cellular health e.g., growth 
defects such as slower doubling times which suggests metabolic re-wiring 
(Figure 8), the production of ROS (as seen in S. cerevisiae WT and mutants in 
Figure 19A) and loss of viability (Figure 11) have occurred. These all suggest 
that finding the compensatory points of metabolism to target for future drug 
development may be the way to progress. 
 
4.4 Inhibition of SDH does not lead to ROS accumulation 
in C. glabrata 
 
The most surprising finding of the C. glabrata experiments was that LND treated 
cells produced regular levels of ROS compared to wild type and especially 
nowhere near the levels which could be deemed lethal or induce cellular stress. 
This contradicted literature that showed that measuring of ROS formation by 
reduced FAD or ubiquinone site by use of a DCF fluorescence produced ROS 
levels higher in LND than that of TTFA treated cells. (Guo et al., 2016). The 




complex II by means of ubiquinone reduction, similar to TTFA but to produce a 
higher level of ROS production than TTFA when TTFA has shown to be a more 
potent inhibitor for complex II. This finding suggests that C. glabrata do not 
utilise the ETC when SDH is inhibited and supports the theory in section 4.3 
which suggests that a disruption along the ETC causes re-wiring of the 
metabolic pathway.  
 
For future work it would be crucial to repeat the same experiment to see if the 
same result occurs and also to run the same experiment but to use NPA (a 
succinate analogue which inhibits succinate-oxidation enzymatic activity) and 
TTFA (inhibition occurs by binding of TTFA to two ubiquinone binding sites) on 
C. glabrata. This would rule out whether this is a conserved response to LND or 
whether it is a general response to complex II inhibitors with differing 
mechanisms of actions. 
 
4.5 SDH2 and IDH2 produce the highest number of ROS 
cells amongst the S. cerevisiae TCA cycle 
 
The flow cytometry analysis of the S. cerevisiae TCA single knockout mutants 
showed that IDH2 and SDH2 enzymes are important intermediates of the TCA 
cycle and without their presence cause the highest ROS cells. This gave 
assurance that the SDH does in fact play a crucial role in the cells energy 
homeostasis and would be the ideal drug target compared to IDH due to the 




already been identified through exome sequencing of colon tumor and 
glioblastoma multiforme (GBM) (Parsons et al., 2008). Since these discoveries, 
IDH mutations have been observed in several other tumor types, including acute 
myeloid leukemia (AML), chondrosarcoma, and intrahepatic 
cholangiocarcinoma. Currently, phase I studies of mutant IDH inhibitors are 
currently ongoing in patients with IDH-mutant hematologic and solid tumors, 
with early data in hematologic tumors suggesting a manageable safety profile as 
well as clinical benefit. Inhibition of mutant IDH shows promise as a treatment 
approach in hematologic malignancies, with further development ongoing in 
solid tumors and glioma. The mutant IDH inhibitors may have clinical utility both 
as single agents and in combination strategies that target additional oncogenic 
pathways (Dang, Yen and Attar, 2016). The flow cytometry data was not 
statistically analysed due to time constraints so it cannot be said whether it 
happened by chance. For future work, it would be beneficial to create C. 
glabrata transformants with single knockout mutants of the TCA cycle in order to 
see whether both species share the same ROS characteristics. The TTFA 
treated cells (Figure 18) led to a very pronounced effect in stationary phase that 
may suggest a complete loss of respiration in S. cerevesiae, so this future work 








4.6 Retrograde pathway (RTG) enabling upon 
administration of LND 
 
 
Figure 24. The retrograde pathway enables respiratory- deficient cells to 
maintain glutamate supplies by providing substrates for ⍺-ketoglutarate. 
 
As the project has been shown that there is some effect on growth and viability 
upon SDH inhibition, it led to investigating the role of compensatory pathways. 
The RTG and glyoxylate cycle could potentially be the systems in which future 
work could design a rational inhibitory drug combination. The first step was to 
carry out the following study.  
The most detailed information on the mechanism of retrograde signalling comes 
from studies of the CIT2 gene. Since its discovery as a retrograde-responsive 
gene (Liao et al., 1991), CIT2 has served as a prototypical readout for the yeast 
retrograde response. The ONPG assay allows for allows colorimetric measuring 
of the activity of the CIT2 promoter which is an indicator for -galactosidase 




were examined to see whether LND was causing an upregulation of the RTG in 
response to a faulty TCA cycle. Upon administration of LND, all mutants saw an 
increase in CIT2 levels except for icl1 (which is located within the glyoxylate 
cycle). This suggests that ICL1 mediates the glyoxylate cycle and ultimately 
without it, the cells would not be able to synthesis the necessary intermediates 
by utilising other carbon sources. 
A study has already shown the effects of icl1 deletion on C. glabrata and it 
seems to show similar effects as shown by the S. cerevisiae analysis in this 
project. The study showed that that disruption of icl1 rendered C. glabrata 
unable to utilise acetate, ethanol or oleic acid. In addition, ∆icl1l cells displayed 
significantly reduced biofilm growth in the presence of several alternative carbon 
sources. It was also found that icl1 is crucial for the survival of C. glabrata in 
response to macrophage engulfment. Disruption of icl1 also conferred a severe 
attenuation in the virulence of C. glabrata in the mouse model of invasive 
candidiasis (Chew et al., 2019). The study concluded that a functional glyoxylate 
cycle is essential to utilise certain alternative carbon sources in vitro and to 
display full virulence in vivo. Also, as macrophage engulfed C. glabrata have 
shown that key metabolic enzymes in the glyoxylate cycle were ICL1 and MLS1. 
(Chew, Chee and Than, 2019), by inhibiting ICL1, it would suggest that it would 
render the pathogen more vulnerable to the immune response within humans. 
To see the importance of ICL1 in both species reinforces the rationale that ICL1 
inhibitors could be a potential anti-fungal drug for the future, whether in 






4.7 Mitochondrial Succinyl-CoA may cause global cellular 
effects via Succinylation 
 
One finding which still needs answering from this is project is what mechanism 
of action LND has due to its effects not being related to respiration. Unlike TTFA 
which seems to produce high ROS via the ETC. One theory is how 
Succinylation could be the modification that is causing global cellular effects and 
is mediated within the mitochondria. This would suggest that Succinyl-CoA 
would in fact be more important than Succinate with regards to LND’s future as 
a potential anti-fungal treatment. 
 
Succinylation is a posttranslational modification where a succinyl group (-CO-
CH2-CH2-CO2H) is added to a lysine residue of a protein molecule. 
Succinylation is an area with very little research but could be just as much 
important for cellular signalling as acetylation. Lysine Succinylation has been 
previously shown to occur in the active site of homoserine trans-succinylase 
(Rosen et al., 2004). What still remains a mystery are both the mechanisms of 
action of Succinylation and the Succinyl donor to Lysine. 
 
More recently a very in-depth analysis of Succinylation sites in S. cerevisiae, 
uncovered that what was previously understood in terms of the number of 
Succinylation sites was in fact far lower than there actually is. Previous studies 
suggested that there were 4 proteins and 7 Succinylation sites (Xie et al., 2012) 
but recently it has shown that there is in fact 474 proteins and 1345 




also shown that any slight changes in Succinyl-CoA within the mitochondria 
causes changes in every Lysine Succinylation site globally (Weinert et al., 2013) 
and also considering that any abundant protein with a Lysine residue is able to 
perform Lysine Succinylation, this highlights just how impactful LND acting on 
SDH to increase Succinyl-CoA levels within the mitochondria can be. 
As Succinyl-CoA and succinate are mainly formed in the mitochondria via the 
TCA cycle or by fatty acid oxidation, this would suggest that defects within the 
TCA cycle that result in differing levels of Succinyl-CoA would produce global 
effects which are indirectly related to the mitochondria. If this was occurring, it 
would suggest that changes would be impacted are within the cytoplasm, 
nuclear expression or cell wall rearrangements. The key enzymes of the TCA 
cycle which have most effect on Succinyl-CoA levels are the enzymes KGD1, 
LSC1 and SDH2 (Figure 24).  
 
 
Figure 24. A view of the important steps (as seen in black) and the enzymes (as 
seen in red) involved with Succinyl-CoA within the TCA cycle. 
 
-ketoglutarates conversion to succinyl-CoA occurs by the -ketoglutarate 
dehydrogenase complex (composed of KGD1, KGD2, and LPD1). Succinyl-CoA 
is then converted to Succinate by succinyl-CoA ligase (LSC1 is the  subunit 
and LSC2 is the  subunit of the complex). Succinate undergoes catalysed 
oxidation of fumarate in the TCA which in turns donates electrons to ubiquinone 




project due to time restraints is that inhibiting complex II plays a major role in the 
glyoxylate RTG signalling via Succinylation. The kgd1 strain lowers Succinyl-
CoA levels as the essential enzyme to convert it is missing which means KGD 
levels pool within the TCA cycle, the opposite effects occur with lsc1 as 
Succinyl-CoA can not be converted to Succinate so pooling of Succinyl-CoA 
occurs. This is already apparent as it has been shown that kgd1 mutant grown 
on galactose media shows a 4-fold decrease in global Lysine Succinylation and 
a 6-fold mitochondrial Lysine Succinylation (Weinert et al., 2013). In contrast, 
lsc1 mutant showed a 3-fold increase in global Lysine Succinylation and a 3-
fold increase Lysine Succinylation (Weinert et al., 2013). Furthermore, one step 
further in the TCA cycle is overlooked as SDH inhibition would also inhibit the 
reversible conversion of Succinate to Succinyl-CoA levels. Any deficiency within 
these enzymes greatly impact Succinyl-CoA. Another question for further 
experiments would be if Succinyl-CoA acts as a regulator and can traverse the 
Mitochondrial membrane when levels are high or if levels are low within the 
mitochondria then cytoplasmic Succinyl-CoA can be salvaged in. If this were the 
case, this could suggest that depleted Succinyl-CoA by SDH2 inhibitors such as 
LND are quickly replenished if the drug is not as potent as TTFA. 
 
Another question is if S. cerevisiae infact do not have any form of succinyl-
transferase then this suggests that Lysine Succinylation occurs to chemical 





Figure 25. Succinylation of Enzymes involved in the Tricarboxylic Acid Cycle, 
the Urea Cycle, and Fatty Acid Oxidation. Succinylated enzymes identified in 
mouse liver tissue are shown in green ovals, sites that were found to be both 
acetylated and Succinylated are shown as blue circles, sites only found to be 
Succinylated are shown as red circles. The enzymes shown are pyruvate 
dehydrogenase component  subunit  alpha  (PDHA1),  citrate synthase  (CS),  
aconitate  hydratase (ACO2),isocitrate dehydrogenase (IDH2), dihydro-
lipoamide S-succinyl transferase (DLST), succinyl-CoA ligases G1, G2, and A1 
(SUCLG1, SUCLG2,and SUCLA1), succinate dehydrogenase (SDHA), fumarate 
hydratase (FH), malate dehydrogenase 1and 2 (MDH1 and MDH2), glutamate 
dehydrogenase (GLUD1), carbamoyl phosphate synthetase I(CPS1), ornithine 
transcarbamoylase (OTC), argi-ninosuccinate synthetase (ASS), argininosucci-
nate lyase (ASL), arginase 1 (ARG1), short-,medium-,  long-,  and  very-long-
chain-specificacyl-CoA  dehydrogenases  (ACADS,  ACADM,ACADL, and 
ACADVL), enoyl-CoA delta isom-erase 1 (ECI1), peroxisomaltrans-2-enoyl-
CoAreductase  (PECR),  enoyl-CoA  hydratase/3,2-trans-enoyl-CoA  
isomerase,3-hydroxyacyl-CoAdehydrogenase (EHHADH), long-chain enoyl-








The interesting point to take from the ONPG data (Figure 22) and the mouse 
liver data shown (Figure 25) is that the promising enzymes found in ONPG 
correspond with those with the majority Succinylation sites to Acetylation sites in 
both the TCA cycle and the fatty acid oxidation. This further suggests that CIT2 
levels via the glyoxylate cycle could in fact caused by Succinylation. The 
defected TCA cycle caused Succinyl-CoA levels to be the key factor. Steps 
before Succinyl-CoA in the TCA cycle generally show a lowered level of CIT2 
compared to those enzymes after Succinyl-CoA and especially those enzymes 
found within the glyoxylate cycle. 
 
4.8 Investigating LSC2 for conserved fungal specific 
regions 
 
From the Succinylation investigation that highlighted that LSC as an enzyme 
caused an upregulation of Succinylation by means of Succinyl-CoA and also 
from the lsc2 growth curve (Figure 18D) which showed the most shallow log 
phase of all mutants and also the loss of respiration in stationary phase, this led 
to investigating further if the DNA sequence of LSC2 had any conserved fungal 








Figure 26. Highlighting the fungal specific Tyrosine in LSC2 which was 
conserved within fungal species and not present in both H. sapiens and H. 
musculus. 
 
The tyrosine is quite an interesting amino acid to be conserved as it’s a 
phosphorylation residue. It could be a relatively simple residue to modify and 
this led to investigating the structure of the S. cerevisiae LSC2 in comparison to 
the H. sapiens equivalent. The fungal specific tyrosine in Figure 27 can be seen 





Figure 27. A PyMOL overlay structures of the beta subunits of Succinate ligase 
in H.sapiens and S.cerevisiae. The fungal specific Tyr seen in red. 
 
 
Figure 28. (A) A PyMOL stick view of the fungal specific Tyrosine. (B) Tyrosine 





Residue modifications were performed to replace the fungal specific Tyrosine 
with either an Alanine or Glutamate. Due to time constraints, this investigation 
could not be continued. For future work, it would be beneficial to mutate the 
residue to alanine (which cannot be phosphorylated) or glutamate (which acts 
as a mimic of the phosphate group presence) and see what the effects are 
within LSC2. Protein phosphorylation is an important cellular regulatory 
mechanism as many enzymes and receptors are activated/deactivated by 
phosphorylation and dephosphorylation events, by means of kinases and 
phosphatases. Such inhibitors as the kinase inhibitors have been shown to be 
valuable for the treatment of cancer (Ardito et al., 2017). It would be ideal to see 
if it would be as beneficial in the fungal model. If the mutation of this residue led 
to a loss in SDH activity or loss of fitness, then would be worth approaching as a 
target. Future research would be crucial to find out what the residue does. 
Questions which would need answering are if it effects SDH assembly or 
interaction with substrate? Or whether it has any impact on stability or 
degradation? 
 
4.9 Concluding remarks 
 
LND has shown to cause significant anti-fungal properties which warrant future 
investigations. Such as its pronounced reduction in the C. glabrata biofilm and 
its ability to reduce colony formation whilst causing flocculation which indicate 
cell wall stress responses. Despite LND showing through respirometry analysis 
that C. glabrata not utilise the ETC when SDH is inhibited, it does suggest that it 




weak points within the glyoxylate the project were found to be ICL1 (within the 
glyoxylate cycle) and LSC2 (within the TCA cycle). Future research on 
combinational drug therapy of using LND alongside inhibitors of ICL1 or LSC2 





























1. Alexander, B. D. et al. (2013) ‘Increasing echinocandin resistance in 
candida glabrata: Clinical failure correlates with presence of FKS 
mutations and elevated minimum inhibitory concentrations’, Clinical 
Infectious Diseases. doi: 10.1093/cid/cit136. 
2. Ardito, F. et al. (2017) ‘The crucial role of protein phosphorylation in cell 
signalingand its use as targeted therapy (Review)’, International Journal 
of Molecular Medicine. doi: 10.3892/ijmm.2017.3036. 
3. Barbosa, A. D. et al. (2012) ‘Activation of the Hog1p kinase in Isc1p-
deficient yeast cells is associated with mitochondrial dysfunction, 
oxidative stress sensitivity and premature aging’, Mechanisms of Ageing 
and Development. doi: 10.1016/j.mad.2012.03.007. 
4. Barros, M. H., Netto, L. E. S. and Kowaltowski, A. J. (2003) ‘H 2 O 2 
generation in Saccharomyces cerevisiae respiratory pet mutants: Effect 
of cytochrome c’, Free Radical Biology and Medicine. doi: 
10.1016/S0891-5849(03)00307-1. 
5. Bhattacharya, K. et al. (2014) ‘Mahanine, a novel mitochondrial complex-
III inhibitor induces G0/G1 arrest through redox alteration-mediated DNA 
damage response and regresses glioblastoma multiforme’, American 
Journal of Cancer Research. 
6. Brun, S. et al. (2004) ‘Mechanisms of Azole Resistance in Petite Mutants 
of Candida glabrata’, Antimicrobial Agents and Chemotherapy. doi: 
10.1128/AAC.48.5.1788-1796.2004. 
7. Brun, S. et al. (2005) ‘Biological consequences of petite mutations in 
Candida glabrata’, Journal of Antimicrobial Chemotherapy. doi: 
10.1093/jac/dki200. 
8. Butler, G. et al. (2009) ‘Evolution of pathogenicity and sexual 
reproduction in eight Candida genomes’, Nature. doi: 
10.1038/nature08064. 
9. Castanheira, M. et al. (2017) ‘Monitoring antifungal resistance in a global 
collection of invasive yeasts and molds: Application of CLSI 
epidemiological cutoff values and whole-genome sequencing analysis for 
detection of azole resistance in Candida albicans’, Antimicrobial Agents 
and Chemotherapy. doi: 10.1128/AAC.00906-17. 
10. Cheng, G. et al. (2019) ‘Targeting lonidamine to mitochondria mitigates 
lung tumorigenesis and brain metastasis’, Nature Communications. doi: 
10.1038/s41467-019-10042-1. 
11. Chew, S. Y. et al. (2019) ‘Glyoxylate cycle gene ICL1 is essential for the 
metabolic flexibility and virulence of Candida glabrata’, Scientific Reports. 
doi: 10.1038/s41598-019-39117-1. 
12. Chew, S. Y., Chee, W. J. Y. and Than, L. T. L. (2019) ‘The glyoxylate 
cycle and alternative carbon metabolism as metabolic adaptation 
strategies of Candida glabrata: Perspectives from Candida albicans and 
Saccharomyces cerevisiae’, Journal of Biomedical Science. doi: 
10.1186/s12929-019-0546-5. 
13. Cleveland, A. A. et al. (2012) ‘Changes in incidence and antifungal drug 




surveillance in Atlanta and Baltimore, 2008-2011’, Clinical Infectious 
Diseases. doi: 10.1093/cid/cis697. 
14. Dang, L., Yen, K. and Attar, E. C. (2016) ‘IDH mutations in cancer and 
progress toward development of targeted therapeutics’, Annals of 
Oncology. doi: 10.1093/annonc/mdw013. 
15. De Groot, P. W. J. et al. (2008) ‘The cell wall of the human pathogen 
Candida glabrata: Differential incorporation of novel adhesin-like wall 
proteins’, Eukaryotic Cell. doi: 10.1128/EC.00284-08. 
16. Dhar, R. (2020) ‘Role of Mitochondria in Generation of Phenotypic 
Heterogeneity in Yeast’, Journal of the Indian Institute of Science. doi: 
10.1007/s41745-020-00176-3. 
17. Ferrari, S. et al. (2009) ‘Gain of function mutations in CgPDR1 of 
Candida glabrata not only mediate antifungal resistance but also 
enhance virulence’, PLoS Pathogens. doi: 10.1371/journal.ppat.1000268. 
18. Ferrari, S. et al. (2011) ‘Loss of mitochondrial functions associated with 
azole resistance in Candida glabrata results in enhanced virulence in 
mice’, Antimicrobial Agents and Chemotherapy. doi: 
10.1128/AAC.01271-10. 
19. Fidel, P. L., Vazquez, J. A. and Sobel, J. D. (1999) ‘Candida glabrata: 
Review of epidemiology, pathogenesis, and clinical disease with 
comparison to C. albicans’, Clinical Microbiology Reviews. doi: 
10.1128/cmr.12.1.80. 
20. FLORIDI, A. et al. (1988) ‘Lonidamine‐Induced Membrane Permeability 
and the Effect of Adriamycin on the Energy Metabolism of Ehrlich Ascites 
Tumor Cells’, Annals of the New York Academy of Sciences. doi: 
10.1111/j.1749-6632.1988.tb22350.x. 
21. Grant, C. M., MacIver, F. H. and Dawes, I. W. (1997) ‘Mitochondrial 
function is required for resistance to oxidative stress in the yeast 
Saccharomyces cerevisiae’, FEBS Letters. doi: 10.1016/S0014-
5793(97)00592-9. 
22. Guo, L. et al. (2016) ‘Inhibition of mitochondrial complex II by the 
anticancer agent lonidamine’, Journal of Biological Chemistry. doi: 
10.1074/jbc.M115.697516. 
23. Hägerhäll, C. (1997) ‘Succinate: quinone oxidoreductases’, Biochimica et 
Biophysica Acta (BBA) - Bioenergetics. doi: 10.1016/s0005-
2728(97)00019-4. 
24. Hargreaves, I. P. et al. (2007) ‘Inhibition of mitochondrial complex IV 
leads to secondary loss complex II-III activity: Implications for the 
pathogenesis and treatment of mitochondrial encephalomyopathies’, 
Mitochondrion. doi: 10.1016/j.mito.2007.02.001. 
25. Healey, K. R. and Perlin, D. S. (2018) ‘Fungal resistance to 
echinocandins and the MDR phenomenon in Candida glabrata’, Journal 
of Fungi. doi: 10.3390/jof4030105. 
26. Hu, Z. et al. (2016) ‘Mitochondrial defects confer tolerance against 
cellulose deficiency’, Plant Cell. doi: 10.1105/tpc.16.00540. 
27. Hytti, M. et al. (2019) ‘Antimycin A-Induced Mitochondrial Damage 
Causes Human RPE Cell Death despite Activation of Autophagy’, 
Oxidative Medicine and Cellular Longevity. doi: 10.1155/2019/1583656. 




NADH-quinone oxidoreductase of Saccharomyces cerevisiae 
mitochondria: The enzyme expressed in Escherichia coli acts as a 
member of the respiratory chain in the host cells’, FEBS Letters. doi: 
10.1016/S0014-5793(97)01533-0. 
29. Koszul, R. et al. (2003) ‘The complete mitochondrial genome sequence 
of the pathogenic yeast Candida (Torulopsis) glabrata’, FEBS Letters. 
doi: 10.1016/S0014-5793(02)03749-3. 
30. Kullberg, B. J. and Arendrup, M. C. (2015) ‘Invasive candidiasis’, New 
England Journal of Medicine. doi: 10.1056/NEJMra1315399. 
31. Kregiel, D. (2012) ‘Succinate Dehydrogenase of Saccharomyces 
cerevisiae – The Unique Enzyme of TCA Cycle – Current Knowledge and 
New Perspectives’, in Dehydrogenases. doi: 10.5772/48413. 
32. Kuranda, K. et al. (2006) ‘Investigating the caffeine effects in the yeast 
Saccharomyces cerevisiae brings new insights into the connection 
between TOR, PKC and Ras/cAMP signalling pathways’, Molecular 
Microbiology. doi: 10.1111/j.1365-2958.2006.05300.x. 
33. Leadsham, J. E. and Gourlay, C. W. (2010) ‘CAMP/PKA signaling 
balances respiratory activity with mitochondria dependent apoptosis via 
transcriptional regulation’, BMC Cell Biology. doi: 10.1186/1471-2121-11-
92. 
34. Leavesley, H. B. et al. (2008) ‘Interaction of cyanide and nitric oxide with 
cytochrome c oxidase: Implications for acute cyanide toxicity’, 
Toxicological Sciences. doi: 10.1093/toxsci/kfm254. 
35. Li, D. et al. (2011) ‘Enzymatic dysfunction of mitochondrial complex i of 
the candida albicans goa1 mutant is associated with increased reactive 
oxidants and cell death’, Eukaryotic Cell. doi: 10.1128/EC.00303-10. 
36. Liao, X. S. et al. (1991) ‘Intramitochondrial functions regulate 
nonmitochondrial citrate synthase (CIT2) expression in Saccharomyces 
cerevisiae.’, Molecular and Cellular Biology. doi: 10.1128/mcb.11.1.38. 
37. Montagna, M. T. et al. (2014) ‘Candidemia in Intensive Care Unit: A 
nationwide prospective observational survey (GISIA-3 study) and review 
of the European literature from 2000 through 2013’, European Review for 
Medical and Pharmacological Sciences. 
38. Niimi, K. et al. (2006) ‘Overexpression of Candida albicans CDR1, CDR2, 
or MDR1 does not produce significant changes in echinocandin 
susceptibility’, Antimicrobial Agents and Chemotherapy. doi: 
10.1128/AAC.50.4.1148-1155.2006. 
39. Parsons, D. W. et al. (2008) ‘An Integrated Genomic Analysis of’, 
Science. 
40. Pfaller, M. A. and Diekema, D. J. (2007) ‘Epidemiology of invasive 
candidiasis: A persistent public health problem’, Clinical Microbiology 
Reviews. doi: 10.1128/CMR.00029-06. 
41. Philip, B. and Levin, D. E. (2001) ‘Wsc1 and Mid2 Are Cell Surface 
Sensors for Cell Wall Integrity Signaling That Act through Rom2, a 
Guanine Nucleotide Exchange Factor for Rho1’, Molecular and Cellular 
Biology. doi: 10.1128/mcb.21.1.271-280.2001. 
42. Public Health England (2017) ‘Voluntary surveillance of candidaemia in 





43. Qin, Y. et al. (2019) ‘Heterogeneity in respiratory electron transfer and 
adaptive iron utilization in a bacterial biofilm’, Nature Communications. 
doi: 10.1038/s41467-019-11681-0. 
44. Rai, M. N. et al. (2012) ‘Functional Genomic Analysis of Candida 
glabrata-Macrophage Interaction: Role of Chromatin Remodeling in 
Virulence’, PLoS Pathogens. doi: 10.1371/journal.ppat.1002863. 
45. Ramage, G. et al. (2012) ‘Fungal biofilm resistance’, International Journal 
of Microbiology. doi: 10.1155/2012/528521. 
46. Rodrigues, M. L. (2018) ‘The multifunctional fungal ergosterol’, mBio. doi: 
10.1128/mBio.01755-18. 
47. Rosen, R. et al. (2004) ‘Probing the active site of homoserine trans-
succinylase’, FEBS Letters. doi: 10.1016/j.febslet.2004.10.037. 
48. Ruy, F., Vercesi, A. E. and Kowaltowski, A. J. (2006) ‘Inhibition of specific 
electron transport pathways leads to oxidative stress and decreased 
Candida albicans proliferation’, Journal of Bioenergetics and 
Biomembranes. doi: 10.1007/s10863-006-9012-7. 
49. Samokhvalov, V., Ignatov, V. and Kondrashova, M. (2004) ‘Inhibition of 
Krebs cycle and activation of glyoxylate cycle in the course of 
chronological aging of Saccharomyces cerevisiae. Compensatory role of 
succinate oxidation’, Biochimie. doi: 10.1016/j.biochi.2003.10.019. 
50. Sharma, L., Lu, J. and Bai, Y. (2009) ‘Mitochondrial Respiratory Complex 
I: Structure, Function and Implication in Human Diseases’, Current 
Medicinal Chemistry. doi: 10.2174/092986709787846578. 
51. She, X. et al. (2015) ‘Fungal-specific subunits of the Candida albicans 
mitochondrial complex I drive diverse cell functions including cell wall 
synthesis’, Cellular Microbiology. doi: 10.1111/cmi.12438. 
52. Shingu-Vazquez, M. and Traven, A. (2011) ‘Mitochondria and fungal 
pathogenesis: Drug tolerance, virulence, and potential for antifungal 
therapy’, Eukaryotic Cell. doi: 10.1128/EC.05184-11. 
53. Silva, S. et al. (2009) ‘Biofilms of non-Candida albicans Candida species: 
Quantification, structure and matrix composition’, Medical Mycology. doi: 
10.3109/13693780802549594. 
54. Silva, S. et al. (2012) ‘Candida glabrata, Candida parapsilosis and 
Candida tropicalis: Biology, epidemiology, pathogenicity and antifungal 
resistance’, FEMS Microbiology Reviews. doi: 10.1111/j.1574-
6976.2011.00278.x. 
55. Sun, F. et al. (2005) ‘Crystal structure of mitochondrial respiratory 
membrane protein Complex II’, Cell. doi: 10.1016/j.cell.2005.05.025. 
56. Sun, N. et al. (2019) ‘Unique, diverged, and conserved mitochondrial 
functions influencing candida albicans respiration’, mBio. doi: 
10.1128/mBio.00300-19. 
57. Sundstrom, P. (2002) ‘Adhesion in Candida spp’, Cellular Microbiology. 
doi: 10.1046/j.1462-5822.2002.00206.x. 
58. Torres, J. et al. (2002) ‘Regulation of the cell integrity pathway by 
rapamycin-sensitive TOR function in budding yeast’, Journal of Biological 
Chemistry. doi: 10.1074/jbc.M205408200. 
59. Vermitsky, J. P. and Edlind, T. D. (2004) ‘Azole resistance in Candida 




for a Pdr1-like transcription factor’, Antimicrobial Agents and 
Chemotherapy. doi: 10.1128/AAC.48.10.3773-3781.2004. 
60. Vermitsky, J. P. et al. (2006) ‘Pdr1 regulates multidrug resistance in 
Candida glabrata: Gene disruption and genome-wide expression studies’, 
Molecular Microbiology. doi: 10.1111/j.1365-2958.2006.05235.x. 
61. Watanabe, T. et al. (2006) ‘Hyphal formation of Candida albicans is 
controlled by electron transfer system’, Biochemical and Biophysical 
Research Communications. doi: 10.1016/j.bbrc.2006.07.066. 
62. Weinert, B. T. et al. (2013) ‘Lysine succinylation is a frequently occurring 
modification in prokaryotes and eukaryotes and extensively overlaps with 
acetylation’, Cell Reports. doi: 10.1016/j.celrep.2013.07.024. 
63. Wojtovich, A. P. et al. (2013) ‘Physiological consequences of complex II 
inhibition for aging, disease, and the mKATP channel’, Biochimica et 
Biophysica Acta - Bioenergetics. doi: 10.1016/j.bbabio.2012.12.007. 
64. Xia, M. F. et al. (2019) ‘Communication between mitochondria and other 
organelles: a brand-new perspective on mitochondria in cancer’, Cell and 
Bioscience. doi: 10.1186/s13578-019-0289-8. 
65. Xie, Z. et al. (2012) ‘Lysine succinylation and lysine malonylation in 
histones’, in Molecular and Cellular Proteomics. doi: 
10.1074/mcp.M111.015875. 
66. Yamashita, K. et al. (2019) ‘The Novel Arylamidine T-2307 Selectively 
Disrupts Yeast Mitochondrial Function by Inhibiting Respiratory Chain 

































































































































































































Fig 29. Growth assays of C. glabrata clinical isolates with LND and DMSO in 
RPMI media over 40 hours. (A) Clinical isolate 30261 WT growth comparison 
with LND treated cells. (B) Clinical isolate 30261 WT growth comparison with 
DMSO treated cells. (C) Clinical isolate 027884 WT growth comparison with 
LND treated cells. (D) Clinical isolate 027884 WT growth comparison with 
DMSO treated cells. (E) Clinical isolate 028987 WT growth comparison with 
LND treated cells. (F) Clinical isolate 028987 WT growth comparison with 
















































Appendix 2 – S. Cerevisiae WT and TCA mutant growth 















































































Fig 30. Growth assays of S. Cerevisiae WT4741 and TCA mutants with TTFA in 
YPD media over 24 hours. (A)WT (B)Δcit1 (C)Δaco1 (D)Δkgd1 (E)Δsdh2 
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